Studies in Experimental Hypertension and the Renin-Angiotensin System by Wallace, Elisabeth Carol Hislop
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
STUDIES IN EXPERIMENTAL HYPERTENSION 
AND THE RENIN-ANGIOTENSIN SYSTEM.
by
(5) ELISABETH CAROL HISLOP WALLACE, B.Sc.
Thesis submitted to the University of Glasgow for 
the degree of Master of Science (Medical Science) 
in the Faculty of Medicine.
M.R.C. Blood Pressure Unit,
Western Infirmary,
Glasgow Gil 6NT.
Scotland. September, 1988
ProQuest Number: 10987047
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10987047
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
CONTENTS.
Page No.
Index of Tables 6
List of Figures 7
Acknowledgements 10
Summary 11
Chapter 1 Review of the literature 14
1.1 Introduction 14
1.2 The renin-angiotensin system, historical
background 15
1.3 Components of the renin-angiotensin system 17
1. Angiotensinogen 18
2. Renin 19
3. Angiotensin I 26
4. Angiotensin converting enzyme 26
5. Angiotensin II 28
6. Angiotensin III 33
1.4 Inhibitors of the renin-angiotensin system 34
1. Structural analogues 34
2. Angiotensin converting enzyme inhibitors 35
3. Renin inhibitors 37
1.5 Experimental renovascular hypertension,
historical background 39
1.6 Role of renin in renovascular hypertension,
acute and chronic phases 40
1.7 Autoregulatory theory of chronic renal
2.
hypertension 44
1.8 A possible second effect of angiotensin II
on blood pressure in two-kidney, one clip 
hypertension 47
1.9 The present study 49
Chapter 2 Materials and methods 51
2.1 Rats 51
2.2 Preparation of renal hypertensive animals 51
1. Construction of renal artery clip 51
2. Clipping of renal artery 52
2.3 Catheterisation 53
1. Carotid artery catheters 53
2. Aortic and vena caval catheters 55
2.4 Experimental cages 60
1. Short-term studies 60
2. Long-term studies 61
2.5 Blood pressure measurement 63
1. Measurement of arterial pressure 63
2. Measurement of heart rate 65
3. Measurement of systolic blood pressure 65
2.6 Continuous intravenous infusion 66
1. Captopril 66
2.7 Injections 66
1. Teprotide 67
2. Angiotensin I 67
3. Captopril 68
2.8 Blood sampling 68
3.
1. Measurement of plasma angiotensin II 69
2. Measurement of plasma renin concentration 71
3. Measurement of angiotensin converting 
enzyme 72
2.9 Statistical methods 73
Chapter 3 Changes in renin and angiotensin II during 
the development of two-kidney, one clip 
hypertension in the rat and the effect of 
acute administration of converting enzyme 
inhibitor 75
3.1 Introduction 75
3.2 Experiment 1(a) 77
1. Experimental design 77
2. Results 78
3.3 Experiment 1(b) 85
1. Experimental design 85
•2. Results 86
3.4 Comment 89
Chapter 4 An examination of the separate effects 
of acute and chronic inhibition of 
converting enzyme on blood pressure in 
two-kidney, one clip rats with 
established hypertension 91
4.1 Introduction 91
1. Experimental design 92
2. Results 94
4.2 Comment 100
Chapter 5 General discussion 101
5.1 Summary of main findings 101
5.2 Sequence of events in the development of the 
hypertension 102
5.3 Mechanisms at work during the different
stages of the hypertension 104
1. Acute stage 104
2. Intermediate stage 105
3. Chronic stage 109
5.4 Possible second mechanisms 114
1. Vascular renin 114
2. The slow pressor effect of
angiotensin II 117
3. Possible mechanisms of the slow pressor 
effect of angiotensin II 118
5.5 Relevance of this study to the disease
in man 123
5.6 Conclusions 124
Appendix 1 125
Appendix 2 126
Appendix 3 130
References 132
INDEX OF TABLES
Table 3. 
Table 3. 
Table 4. 
Table 4.
1 Groups of rats studied
2 Rats studied further
1 Protocol for Experiment 2
2 Correlation between the fall in 
blood pressure with increasing 
duration of captopril infusion 
and basal plasma renin and 
angiotensin II concentrations
Following Page
78
85
92
99
INDEX OF FIGURES
Figure 1. 
Figure 1.
Figure 1.
Figure 1. 
Figure 1.
Figure 2. 
Figure 2. 
Figure 2. 
Figure 2.
Figure 2. 
Figure 3.
Figure 3.
Figure 3. 
Figure 3.
Following page
1 Outline of the renin-angiotensin system. 17
2 Comparison of the N-terminal sequences of
equine., human and rat angiotensinogens 19
3 Formation and metabolism of the
angiotensins 26
4 Teprotide and captopril 36
5 Postulated sequence of events during the
development of hypertension after renal 
artery constriction 45
1 Carotid artery catheter 53
2 Aortic catheter 55
3 IVC catheter 55
4 Position of aortic and vena caval
catheters 57
5 Experimental cage 61
1 Changes in blood pressure, renin and
angiotensin II in two-kidney, one clip 
hypertensive and sham-operated rats 79
2 Changes in systolic blood pressure 
measured sequentially in two-kidney,
one clip and sham-operated rats 80
3 Correlation between mean blood pressure and
log angiotensin II for all clipped rats 82
4 Changes in body weight, packed cell volume
7.
Figure 3.
Figure 3.
Figure 3.
Figure 3.
Figure 4.
Figure 4.
and heart rate in two-kidney, one clip 
hypertensive and sham-operated rats 83
5 Angiotensin II/blood pressure regression 
lines for acute and chronic hypertensive
rats 84
6 Changes in blood pressure, angiotensin II 
and plasma renin concentration in chronic 
and intermediate hypertensive rats given an 
acute injection of angiotensin converting 
enzyme inhibitor nonapeptide and chronic 
hypertensive rats given saline 86
7 Correlation between the fall in blood 
pressure and basal angiotensin II in 
chronic hypertensive rats given converting ' 
enzyme inhibitor 88
8 Mean angiotensin II and blood pressure 
values before and after converting enzyme 
inhibitor for 26 chronic and 12 
intermediate hypertensive rats superimposed 
on the angiotensin II/blood pressure 
regression lines for acute and chronic 
hypertensive rats 89
1 Correlations between manually and computer 
calculated blood pressure for 4 rats 94
2 Blood pressure profile of rats given an 
acute injection of captopril followed by 
a chronic infusion of either dextrose or 
captopril 95
8.
Figure 4 
Figure 4 
Figure 5
Figure 5 
Figure 5
Figure 1 
Figure 2 
Figure 3
3 The acute fall in mean arterial blood 
pressure following injection of captopril
4 Blood pressure response to the 
administration of lOOng angiotensin I
1 Progressive changes in angiotensin II and 
blood pressure during the onset, 
development and establishment of 
hypertension in the two-kidney, one clip 
hypertensive rat in relation to the upward 
parallel shift in the angiotensin II/blood 
pressure found for acute rats to that 
found for chronic rats
2 Feedback mechanism involving vascular 
hypertrophy and arterial pressure
3 Schematic representation of the main 
events in a signalling system activated 
by growth factors
Carotid artery catheter 
Aortic catheter 
Vena caval catheter
96
97
103
120
121
125
129
131
9.
ACKNOWLEDGEMENTS.
I wish to thank Dr J.J. Morton for his
encouragement and advice during the course of this study.
My thanks also go to the following members of the
MRC Blood Pressure Unit staff for their assistance in
various aspects of this work:
Dr A.F. Lever for ongoing interest and advice.
Dr A.J. Balmforth for his help in writing the computer 
programme.
Mr W. Brown for his technical assistance in many matters. 
Dr Alison J. Brown for technical advice concerning the 
construction and implantation of aortic and IVC catheters.
I also express my gratitude to Mr I. Ramsden for his 
excellent illustrations.
SUMMARY.
Blood pressure, angiotensin II and renin content 
were measured in unanaesthetized two-kidney, one clip 
hypertensive rats at 1 and 2 days, at weekly intervals up 
to 10 weeks and at 15 and 20 weeks after clipping. Blood 
pressure was elevated at 1-2 days and remained at this 
level until 2 weeks when there was a further progressive 
rise reaching a plateau at 5-6 weeks after which time 
hypertension was sustained up to 20 weeks. Compared with 
values in sham-operated rats angiotensin II and renin were 
initially increased at 1-2 days but were then supressed 
between 2 and 4 weeks to levels similar to those found in 
the sham-operated rats. Between 5 and 20 weeks 
angiotensin II and renin increased again to high levels. 
There was a significant correlation between angiotensin II 
and blood pressure in acute rats 1-2 days after clipping 
(p<0.05) and in chronic rats 8-20 weeks after clipping 
(pcO.001). There was no difference in the slope of the 
regression lines but the regression line for the chronic 
rats was shifted upwards in a parallel manner.
The acute hypotensive response (-20.3 +/- SD 24.9 
mmHg) in 26 rats given converting enzyme inhibitor was 
related to the basal renin and angiotensin II levels and 
followed the slope of the angiotensin II/blood pressure 
regression line for all chronic rats. Only one out of 26 
rats had its blood pressure reduced to normal levels. In 
12 rats at 4 weeks after clipping when blood pressure was
elevated but angiotensin II was supressed, there was only 
a small fall in blood pressure (-7.1 +/- SD 7.2 mmHg).
This also followed the angiotensin II/blood pressure 
regression line for the chronic rats but at the lower end. 
Blood pressure again was not reduced to normal.
These results suggest that there is no change in 
the net vascular responsiveness to endogenous angiotensin 
II at any stage in this experimental model and that the 
acute effect of angiotensin II on blood pressure is 
determined solely by its position in the same dose 
response curve. Also with the exception of 1-2 days after 
clipping the acute effect of angiotensin II plays only a 
minor role in the hypertension and that some other 
mechanism is of greater importance and begins to have an 
effect as early as 2 weeks after clipping.
In an attempt to elucidate this other mechanism 
the effect on blood pressure of acute and chronic 
suppression of angiotensin II was studied in chronic 
hypertensive two-kidney, one clip rats. Conscious 
chronically catheterized rats were given a bolus injection 
of captopril (2.5 mg/kg) followed by a chronic infusion of 
either dextrose or captopril (lmg/kg/h) lasting 5 days. 
Blood pressure was measured continuously by a computer 
technique. Following the acute injection of captopril, 
arterial blood pressure fell from 165.1 +/- SD 19.4 mmHg 
to a minimum of 137.6 +/- SD 23.3 mmHg after 15 minutes. 
Twelve hours after starting the chronic infusion of 
captopril, blood pressure fell to a minimum of 112.5 +/-
SD 19.4 mmHg. This was significantly lower than after the 
acute injection of captopril. Blood pressure remained 
lower throughout the 5 day infusion ranging on the 5th day 
from 122.1 +/- SD 23.4 to 136.0 +/- SD 30.2 mmHg. In 
contrast, in the rats given dextrose chronically blood 
pressure continued to rise, ranging on the 5th day from
163.6 +/- SD 23.8 to 180.4 +/- SD 22.5 mmHg. Both the 
fall in blood pressure after acute captopril and that 
after chronic captopril were related to pre-treatment 
levels of plasma renin concentration.
These results suggest that in the two-kidney, one 
clip hypertensive rat, angiotensin II, in addition to its 
acute vasoconstrictor property, might contribute to the 
hypertension through a secondary effect.
CHAPTER 1
REVIEW OF THE LITERATURE.
1.1 Introduction.
The most common form of unilateral renal disease 
responsible for the development of elevated blood pressure 
in man is stenosis or occlusion of a renal artery. In 
addition to patient investigation, the use of animal 
models of renal artery stenosis has allowed further study 
of this disease. In particular the extension of 
Goldblatt's dog model (1934) to the rat (Wilson & 
Byrom,1939) resulted in an animal model which mimicked to 
a remarkable extent the disease as seen in man. As will 
be seen from work presented in this thesis, this 
similarity between human renal artery stenosis with 
hypertension and the Goldblatt two-kidney, one clip rat 
model extends to the relationship between changes in blood 
pressure and the renin-angiotensin system; a major causal 
factor implicated in this disease. Such similarities 
emphasise the particular relevance to man of studies 
carried out in this model. The involvement of the 
renin-angiotensin system in renovascular hypertension has 
been extensively studied and while much is understood, the 
story is not yet complete. Today there is still 
disagreement, particularly relating to the long term
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involvement of the renin-angiotensin system in the 
disease.
1.2 The renin-angiotensin system, historical background.
The association between kidney disease and raised 
arterial pressure was first noted by Richard Bright as 
early as 1836. Over 60 years later, influenced by these 
observations. Tigerstedt and Bergman (1898) began to 
investigate the possible endocrine function of the kidney. 
They found that crude saline extracts of rabbit kidneys 
injected into other rabbits produced a pressor response. 
They named this active extract renin. The importance of 
their observaton was disputed for over 30 years until in 
1934 Goldblatt and his colleagues carried out their 
classical experiments in which they produced a 
reproducible model of persistant hypertension in dogs by 
the constriction of both renal arteries with specially 
designed silver clamps. The availability of this model 
stimulated considerable research into the possible humoral 
or neural mechanisms that might cause renal hypertension. 
Page (1935) and Goldblatt, Gross and Hanzal (1937) showed 
that neural factors were not involved in the development 
of the hypertension. These findings pointed to a humoral 
mechanism being responsible and at the end of the 1930’s 
Tigerstedt and Bergman’s original work was confirmed by 
Harrison, Blalock and Mason (1936), Prinzmetal & Friedman
(1936), Landis, Montgomery and Sparkman (1938) and 
Pickering & Prinzmetal (1938). The first biological assay 
for renin was described in 1938 (Pickering & Prinzmetal) 
in which a stable preparation of renin was made as a 
standard and extracts from tissues could be compared with 
this using the blood pressure responses of unanaesthetised 
rabbits.
After the rediscovery of renin it became apparent 
that renin itself did not act directly on the vascular 
system. Kohlstaedt, Helmer and Page (1938) found that 
renin was not pressor in its own right, but that it became 
pressor on incubation with a substance or substances in 
the plasma which they named ’renin activator'. In 1940 
Page & Helmer in their search for a product resulting from 
the interaction of renin and renin activator discovered a 
new pressor substance which they named ’angiotonin’. 
Independently, and at the same time, Braun-Menendez et al. 
(1940) extracted a pressor substance from the venous blood 
of ischaemic kidneys which was shown to have different 
properties from renin. They named this substance 
’hypertensin1 and concluded that the production of 
hypertensin by renin was enzymatic, the substrate for this 
reaction being a blood protein which they named 
’hypertensinogen’. It was soon recognised that angiotonin 
and hypertensin were the same substance and that renin 
activator and hypertensinogen were synonymous, but it was 
not until 1958 (Braun-Menendez & Page) that the two terms, 
angiotonin and hypertensin, were blended to give
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angiotensin.
The first step towards the isolation and 
structural characterisation of angiotensin was made by 
Skeggs et al. (1954) when they demonstrated that two forms 
of angiotensin could be produced from horse plasma 
(designated by them as hypertensin I and II). They 
described the purification of hypertensin I. Peart (1956) 
isolated a pure angiotensin I from ox serum which 
contained eight different amino acids whereas Skeggs et 
al. (1955) showed that their product was a decapeptide 
containing nine different amino acids. Eventually the 
difference was reconciled when the structures of ox 
angiotensin and horse angiotensin were elucidated by 
Elliot & Peart (1956,1957), Lentz et al. (1956) and Skeggs 
et al. (1956). The important difference lay in position 
five in which ox has valine and horse has isoleucine. The 
amino acid sequences of both angiotensin I decapeptide and 
angiotensin II octapeptide were subsequently confirmed by 
synthesis (Schwarz, Bumpus & Page,1957; Rittel et 
al.,1957; Schwyzer et al.,1958a,1958b).
1.3 Components of the renin-angiotensin system.
The renin-angiotensin system is a biochemical 
cascade (Figure 1.1). Renin substrate or angiotensinogen,
17.
Angiotensinogen
Angiotensin I
Renin
Converting enzyme
Angiotensin II
Pressor effect 
Sympathetic stimulation 
AOH secretion
Aldosterone secretion
Thirst
Renal actions
Figure 1.1 Outline of the renin-angiotensin system and 
some of the main actions of angiotensin II.
a glycoprotein, is secreted by the liver into the 
circulation where it is converted to the decapeptide 
angiotensin I by the action of the renal enzyme renin. 
Angiotensin I is in turn converted to the active component 
of the system, the octapeptide angiotensin II. Among 
other properties, angiotensin II acts directly on smooth 
muscle of vascular tissue to raise blood pressure.
1.3:1 Angiotensinogen.
Angiotensinogen is an 0(2 globulin synthesised in the 
liver (Nasjletti & Masson,1971) and released into the 
blood stream. While the liver appears to be its main site 
of synthesis, renin substrate has also been detected in 
the brain (Ganten et al.,1971), vasculature 
(Desjardins-Giasson et al.,1981) and recently mRNA 
angiotensinase sequences have been detected in many 
non-liver sites (Dzau et al.,1986; Ohkubo et al.,1986). 
Early attempts to purify pig angiotensinogen (Skeggs et 
al.,1963) showed the existance of multiple forms, all of 
which were susceptible to conversion by pig renin, and all 
had a molecular weight around 57,000 daltons. A similar 
molecular weight was.found for human angiotensinogen by 
Printz et al. (1977). Although renin will cleave a number 
of synthetic peptide substrates, angiotensinogen is the 
only naturally occurring renin substrate. The minimum 
peptide sequence required for substrate activity is the
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6-13 octapeptide (Skeggs et al.,1957). Renin specifically 
cleaves the bond between amino acid residues at positions 
10 and 11. As can be seen from Figure 1.2 there are some 
species differences in the amino acids at these positions 
and in other positions in the N-terminal sequence. The 
differences are reflected in the species specificity of 
the renin substrate reactions. Human angiotensinogen is 
cleaved only by human renin, whereas other mammalian 
angiotensinogens are cleaved by both human and animal 
renins. These differences have proved to be crucial in 
the development of effective species specific renin 
inhibitors.
1.3:2 Renin.
(i) Properties:
Renal renin is a member of the aspartic proteinase 
group of enzymes which include pepsin, chymosin, cathepsin 
D and various microbial proteinases. It is synthesised 
and stored in, and released from granular cells of the 
juxtaglomerular apparatus (Goormaghtigh,1939). While the 
kidney is the main source of circulating renin, renin 
isoenzymes have been found in other tissues such as the 
uterus and placenta (Bing & Faarup,1966; Symonds, Stanley 
& Skinner,1968), amniotic fluid (Brown et al.,1964), 
adrenal gland (Naruse et al.,1983), salivary gland 
(Werle,1968) and brain (Inagami et al.,1982; Ganten et 
al.,1971;1983). Renin is also present in the vasculature
19.
Renin
1 2 3 4 5 6 7 8 9 10 » 11 12 13 14
Horse asp arg val tyr ile his pro phe his leu leu val tyr ser
Human asp arg val tyr ile his pro phe his leu val ile his thr
Rat asp arg val tyr ile his pro phe his leu leu tyr tyr ser
Figure 1.2 Comparison of the N-terminal sequences 
of equine, human and rat angiotensinogens.
(Thurston et al.,1979; Loudon et al.,1982;1983). More 
recently renin mRNA expression has been identified in a 
range of extra renal sites (Samani et al.,1987; Samani, 
Brammar & Swales,1988). The precise function of these 
extrarenal renins and in particular whether brain renin is 
important in the regulation of blood pressure is far from 
clear (Reid,1977; Ganong,1977), however it is possible 
that angiotensin II generated locally within resistance 
vessels might act to modulate both vascular tone and the 
pressor response to injected angiotensin II 
(Swales,1979;1983a&b; Dzau,1986; Swales & Heagerty,1987). 
This will be discussed in more detail later (see 5.4:1).
Inagami and Murakami (1977) were first to isolate 
renin from pig kidneys in a pure and stable form. They, 
showed it to have a molecular weight of 36,400. Rat renin 
in the form of three isoenzymes was purified in 1978 by 
Matoba, Murakami and Inagami with molecular weights 
35,000, 36,000 and 37,000. Using naturally occurring 
substrates the pH optimum was between 5.5 and 6.5 and the 
average half life in normal rats was 11.5 minutes. Human 
renin was eventually purified in 1980 by Yokosawa et al. 
and shown to have a molecular weight of 40,000. More 
recently the purification of renin has been greatly 
simplified using a new transition state analogue of renin 
substrate (H-77) as an affinity ligand (McIntyre et 
al.,1983).
Renin has been described in an inactive form which 
can be activated by acidification to pH 3.3, by trypsin.
by cooling to -5 C or by kallikrein (Day & Leutcher,1975; 
Atlas, Sealey & Laragh,1978; Sealey et al.,1978; 
Leckie,1981). The physiological importance of inactive 
renin is uncertain and the concept that it may be a 
precursor of renin has yet to be proved (Leckie ,1981).
(ii) Control of renin release:
There are five main interacting mechanisms 
governing the release of renin from the juxtaglomerular 
apparatus:
1. Intrarenal baroreceptors which are thought to respond 
to changes of stretch in the wall of the afferent 
arteriole.
2. The detection of filtered sodium by the macula densa 
(chemoreceptor).
3. The autonomic nervous system and circulating 
catecholamines.
4. Other hormones (angiotensin II and vasopressin).
5. Plasma electrolytes (potassium).
Calcium is recognised as an important 
intracellular link between stimulus and effect in many 
hormonal systems (Rubin,1970) and is present in both 
secretory and smooth muscle cells. In 1977 Peart 
suggested that calcium plays a central role in controlling 
renin secretion, and Baumbach and Leyssac (1977) 
demonstratsd that intracellular rather than extracellular 
calcium was important as regards renin release. This has
led to the view that cytosolic calcium is an intracellular 
signal which regulates renin secretion through the 
baroreceptor, macula densa and neurohormonal pathways. 
Factors which physiologically stimulate renin secretion do 
so by lowering cytosolic calcium and those which inhibit 
secretion do so by raising calcium. This inverse 
relationship is in contrast to most similar secretory 
systems where there is a direct relationship between 
intracellular calcium and secretion. (For a review see 
Fray, Park & Valentine,1987).
1. The intrarenal baroreceptor: The constriction of the
renal arteries of dogs by Goldblatt et al. (1934) first 
indicated that reduced renal perfusion pressure could be a 
stimulus for renin release. In 1959 Tobian, Tomboullan 
and Janecek observed reduced juxtaglomerular cell renal 
perfusion pressure and postulated a renal baroreceptor 
which responded to changes in perfusion pressure. In 1964 
Skinner, McCubbin and Page were first to demonstrate 
increased renin release in response to decreased perfusion 
pressure following graded aortic constriction. It was 
proposed by Tobian (1962) that this baroreceptor or 
’stretch’ receptor was situated on the afferent arteriole, 
the amount of stretch being determined by the perfusion 
pressure and intrarenal tissue pressure. However a recent 
analysis of the strech receptor hypothesis shows that the 
receptor responds most consistently to changes in 
cytosolic calcium (Fray, Lush & Park,1986). High renal
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perfusion pressure increases calcium permeability and 
promotes inflow of calcium thus inhibiting renin 
secretion.
2. The macula densa: Brown et al. (1963) were the first 
to demonstrate the link between sodium intake and changes 
in renin concentration, and Vander & Miller (1964) were 
the first to study in more detail the relationship between 
tubular sodium load and renin secretion. Churchill, 
Churchill and McDonald (1978), using micropuncture 
techniques, have demonstrated a clear inverse relationship 
between renin secretion and sodium load. It is now 
generally believed that the macula densa receptor (or 
chemoreceptor) operates by detecting changes in distal 
tubule fluid composition, either as a consequence of the 
rate of delivery of sodium to the distal tubule, or by the 
rate of transport of sodium by the macula densa. It has 
been suggested that intracellular calcium may be the final 
signal through which the macula densa communicates with 
the juxtaglomerular cell and thus the renin secretory 
process (Fray et al.,1987), increased sodium load being 
linked with an increase in calcium influx to 
juxtaglomerular cells.
3. Autonomic nervous system and catecholamines: The 
granular juxtaglomerular cells are innervated by 
sympathetic fibres (Nilsson,1965; Biava & West,1966; 
Wagermark, Ungerstedt & Ljungqvist,1968) and electrical
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stimulation of the nerves releases renin into the 
circulation (Vander,1965). Renal nerve stimulated renin 
release is blocked by the action of propranalol (Assaykeen 
& Ganong, 1971) indicating that this mechanism probably 
operates via p-receptors.
Scornick and Paladini (1964) were the first to 
demonstrate increased renin release in response to infused 
noradrenaline. In 1970, Ueda et al. confirmed this 
observation and showed that it was accompanied by a 
reduced renal blood flow, glomerular filtration and sodium 
excretion. They also showed that the renin response could 
be blocked by propanalol, suggesting a p-receptor mediated 
mechanism.
p-adrenergic agonists have been shown to stimulate 
renin release by a process involving cyclic AMP. Cyclic 
AMP lowers cytosolic calcium by increasing calcium efflux 
and by sequestering calcium into intracellular storage 
sites (Churchill,1985) and thus calcium appears to be the 
final intracellular signal for the neurohormonal pathway 
of renin secretion. 0C -adrenergic agonists raise 
cytosol-ic calcium by increasing calcium influx and thus 
inhibit renin secretion (Hackenthal, Schwertschlag & 
Taugner,1983).
4. Other hormones: Angiotensin II has an inhibitory
effect on renin secretion (Vander & Geelhoed,1965) and is 
thought to operate through two negative feedback loops.
The first of these is the ’short loop1 (Keeton, Pettinger
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& Campbell,1976) in which angiotensin II acts directly on 
the juxtaglomerular cells via renal receptors similar to 
those in the vasculature (Naftilan & Oparil,1978).
Evidence to support a renal receptor mediated effect comes 
from the observation that the angiotensin receptor 
antagonist Sarl-Ala8-angiotensin II, saralasin, blocked 
the effect. The flong loop’ operates more slowly via 
stimulation of aldosterone with sodium retention and 
consequent expansion of extracellular fluid volume which 
in turn suppresses renin release via the macula densa and 
baroreceptor mechanisms.
Vasopressin also inhibits renin release (Bunag, 
Page & McCubbin,1967). This effect may operate by a 
direct mechanism or indirectly via haemodynamic changes. 
Vandongen (1975) using the isolated perfused rat kidney 
was unable to. demonstrate an effect of vasopressin on 
renin release while Konrads et al. (1978) concluded that 
its ability to suppress renin was independent of its 
vasoconstrictor effect. In this respect Morton, Garcia 
del Rio and Hughes (1982) demonstrated a clear suppressent 
effect on plasma renin concentration in the conscious rat 
at vasopressin infusion rates which had no detectable 
effect on systemic blood pressure.
Again calcium is implicated, calcium influx 
appears to be the inhibitory signal by which angiotensin 
II and vasopressin control renin secretion, both peptides 
promoting calcium influx primarily through voltage 
sensitive channels (Buhrle, Nobiling & Taugner,1985).
25.
5. Other electrolytes: Potassium infused at very low
concentrations inhibits renin release. The mechanism of 
this is not clear but Schneider et al. (1972) have 
suggested that it is an indirect action in which potassium 
inhibits sodium reabsorption in the ascending limb of the 
loop of Henle thereby increasing the sodium load at the 
macula densa which in turn suppresses renin release.
1.3:3 Angiotensin I
The decapeptide angiotensin I is formed by the 
action of renin on renin substrate (Figure 1.3). It has 
been suggested that angiotensin I, at high concentrations, 
may act on the adrenal medulla to release catecholamines 
(Peach, Bumpus & Khairallah,1971) and on the kidney to 
alter blood flow (Itskovitz & McGiff,1974). It is 
possible, however, that the effect is due to angiotensin 
II formed by localised conversion of angiotensin I (Leckie 
et al.,1972; Peach,1977). Certainly, at more 
physiological concentrations it is probable that 
angiotensin I possesses little or no biological action.
1.3:4 Angiotensin Converting enzyme.
Angiotensin converting enzyme is a non specific 
peptidyl dipeptide hydrolase and cleaves bonds of a wide 
variety of amino acids (Yang, Erdos & Levin,1971). It
26.
1 2 3 4 5 6 7 8 9 10 11 12 13 14
H - Asp - Arg - Val - Tyr - lie - His - Pro - Phe - His - Leu - Leu - Tyr - Tyr- Ser Renin
substrate
Renin-
1 2 3 4 5  6 7 8  9 1 0 .
H - Asp - Arg - Val - Tyr - lie - His - Pro - Phe - His - Leu - OH
(rat)
Angiotensin I
Converting
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Figure 1.3 Formation and metabolism of the angiotensins.
converts angiotensin I to angiotensin II by removing the 
C-terminal histidyl leucine dipeptide (Figure 1.3) and 
inactivates bradykinin to peptide fragments. It is now 
accepted that converting enzyme and kininase II, which 
degrades bradykinin, are the same enzyme (Yang, Erdos & 
Levin,1970). Consequently the same enzyme both activates 
a hypertensive mechanism and inactivates a hypotensive 
mechanism. In 1968, Ng & Vane demonstrated in the dog 
that conversion of angiotensin I to angiotensin II in 
plasma was very slow. In contrast, passage of angiotensin 
I through the lungs resulted in large amounts of 
angiotensin II being formed. The lung has since been 
shown to contain large amounts of converting enzyme 
localised in the vascular endothelium of the pulmonary 
arteries (Aiken & Vane,1970; Cushman & Cheung,1972), and 
is the main site for the formation of angiotensin II. 
Converting enzyme is also present in other tissues 
including the kidney (Oshima, Gesce & Erdos,1974), rat 
brain (Yang & Neff,1972), rat testes (Cushman &
Cheung,1971a) and peripheral vascular tissue (Aiken &
Vane,1972; Ryan et al.,1976a; Takada et al.,1982; Miyazaki 
et al.,1984). The converting enzyme-angiotensin I 
reaction has a Km of 5xlO-5M (Cushman & Cheung,1972) 
indicating that it is probably not a rate limiting step in 
the formation of angiotensin II in vivo as the 
circulating concentration of angiotensin I is much lower, 
in the region of 5xlO-llM. (For a review of converting 
enzyme see Erdos,1975).
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1.3:5 Angiotensin II.
(i) Biological properties:
Angiotensin II is recognised as the main effector 
hormone of the renin angiotensin system and has a number 
of important physiological and pharmacological properties. 
The most important are:
1. It has the ability to raise blood pressure both 
acutely and by a slow chronic effect.
2. It affects the central nervous system to raise blood 
pressure, promote drinking, and stimulate vasopressin 
secretion.
3. It interacts with the sympathetic nervous system at 
several points.
4. It stimulates the secretion of aldosterone in the 
adrenal cortex.
5. It has a distinct intrarenal function regulating renal 
haemodynamics.
1. Pressor actions: Angiotensin II is one of the most
potent vasoconstrictor substances known (Oparil &
Haber,1974). It has selectivity for arterial vessels, 
being less potent as a venoconstricter (Folkow, Johansson 
& Mellander,1961). The characteristic response following 
intravenous injection is a prompt rise in blood pressure 
reaching a maximum at about one minute and with a duration 
of response of approximately 5 minutes. If doses are
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large tachyphylaxis may occur (Bock & Gross,1961). The 
blood pressure responses to angiotensin II are partly 
influenced by the prevailing sodium status, there being an 
inverse relationship between dietary sodium intake and 
pressor response. Recent studies indicate that endogenous 
angiotensin II has the ability to regulate the number of 
its own receptors (Gunther, Gimbrone & Alexander,1980; 
Aguilera & Catt,1981; McQueen & Semple,1987). High 
endogenous angiotensin II levels (as seen during low salt 
status) down-regulate the number of receptors resulting in 
a diminished pressor response. Conversely there is 
up-regulation of receptor numbers during high salt intake.
The mechanism by which angiotensin II acts on 
vascular smooth muscle to produce vasoconstriction is 
believed to be an interaction of angiotensin with its 
membrane bound receptor which in turn produces a rise in 
intracellular ionized calcium (Daniels & Kwan,1981) 
producing the contractile response. The interaction of 
angiotensin with its receptor brings about a rise in 
intracellular calcium by increasing the permeability of 
the membrane to calcium through depolarisation and/or an 
effect on receptor operated channels (ROC’s) and also by 
releasing bound calcium within the cell by activation of 
the second messenger inositol triphosphate (Bolton,1979? 
Berridge,1984; Berridge & Irvine,1984; Brock et al.,1985; 
Capponi, Lew & Vallotton,1985; Nabika et al,1985).
As well as a rapid effect on blood pressure, 
angiotensin II also has a slow pressor property raising
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arterial pressure gradually when infused at low doses for 
a prolonged period of time. This effect has been 
demonstrated in the rabbit (Dickinson & Lawrence,1963)f 
dog (McCubbin et al.,1965; Bean et al.,1979), rat (Brown 
et al.,1981; Brown, Clark & Lever,1983) and man (Ames et 
al.,1965). The mechanism of this phenomenon is unclear 
and some possibilities for it will be discussed in detail 
later (5.4.3). These include action of angiotensin II on 
the nervous system, effect of salt and water excretion, 
structural changes in the blood vessel wall and vascular 
renin.
2. Central nervous system: An increase in blood pressure
induced by centrally administered angiotensin has been 
demonstrated in the dog (Lowe & Scroop,1969), cat (Severs 
et al.,1966) and the rat (Fink et al.,1980).
Angiotensin II administered into the central 
nervous system stimulates drinking in several species 
(Epstein, Fitzsimons & Rolls,1970; Fitzsimons, Kucharczyk 
& Richards,1978). The subfornical region appears most 
sensitive to this response with as little as O.lng 
angiotensin II eliciting a drinking response (Simpson & 
Routtenberg, 1973). Recent studies in man in which 
angiotensin was infused into the circulation (Phillips et 
al.,1985) suggest that this response is more 
pharmacological than physiological as it was observed only 
at very high plasma concentrations.
It has been claimed that angiotensin II stimulates
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the secretion of arginine vasopressin from the posterior 
pituitary (Bonjour & Malvin,1970; Mouw et al.,1971; Keil, 
Summy-Long & Severs,1975) This however has not been 
confirmed by other workers (Claybaugh, Share & 
Shimuzu,1972; Shade & Share,1975) and so there is 
controversy as to whether this relatioship is of 
physiological importance. Following angiotensin II 
infusion in man, Padfield & Morton (1977) found increased 
plasma vasopressin but only at supraphysiological levels 
of angiotensin. At more physiological levels, found 
during sod ium depletion, there was no increase in plasma 
vasopressin (Morton et al.,1985). Similarly, in the dog, 
infusion of physiological levels of angiotensin II had no 
effect on the long term control of vasopressin secretion 
(Cowley, Switzer & Skelton,1981).
3. Sympathetic nervous system: There is now good
evidence that some of the effects of angiotensin II result 
from an interaction with the sympathetic nervous system 
(McCubbin & Page,1963; Kaneko et al.,1966). The precise 
mechanism is uncertain but it is believed that there is 
both a postsynaptic and a presynapyic effect. The former 
is thought to involve an increase in the sensitivity of 
the effector to noradrenaline (Zimmerman,1978), while the 
latter is thought to involve an augmentation of the 
outflow of noradrenaline following nerve stimulation 
(Zimmerman & Whitmore,1967), either by inhibiting neuronal 
uptake of noradrenaline (Khairallah,1972) or by increasing
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the amount of transmitter released (Starke,1977).
4. Aldosterone stimulation: The possibility that renin 
might stimulate the synthesis and release of aldosterone 
by the adrenal cortex was suggested by Gross in 1958. In 
1961 Davis et al. demonstrated this effect and at about 
the same time it was shown that angiotensin II was the 
effector hormone (Laragh et al.,1960; Biron et al.,1961). 
There is now little doubt that angiotensin II stimulates 
the synthesis of aldosterone and is probably the major 
factor controlling its secretion in response to alteration 
in sodium balance (Oelkers et al.,1974? Nicholls et
al.,1978).
5. Renal effects: Angiotensin II infused at low doses
results in retention of sodium and water (Malvin & 
Vander,1967; Waugh,1972),and it has been proposed that 
this may be due to angiotensin II exerting a direct 
stimulatory effect on tubular reabsorption (Johnson & 
Malvin,1977). Following the detection of angiotensin II 
within the rat kidney, it has been proposed (Lever &
Peart,1962; Mendelsohn,1979) that there is an intrarenal 
renin system with angiotensin II acting as a local hormone 
regulating renal haemodynamics. (For review see Levens, 
Peach & Carey,1981).
(ii) Destruction of angiotensin II:
The circulating half-life of angiotensin II is 
less than 30 seconds. Although degradative enzymes 
(angiotensinases) are present in blood, angiotensin II is 
catabolised mainly during passage through tissue vascular 
beds including the spleen, limbs, kidney and brain (Hodge, 
Ng & Vane,1967; Ng & Vane,1968; Bakhle, Reynard & Vane 
1969; Bailie & Oparil,1977) Three main groups of enzymes 
have been shown to hydrolyse angiotensin II:
(a) Aminopeptidases or angiotensinase 'A': These degrade
the peptide at the N-terminal bond. This is thought to be 
the main degradative enzyme (Ryan,1974). There are now 
known to be two aminopeptidases; angiotensinase Al which 
is specific for Asnl angiotensin II, and angiotensinase A2 
which is specific for Aspl angiotensin II.
Aminopeptidases have a requirement for calcium.
(b) Endopeptidases or angiotensinase 'B1: These hydrolyse
bonds within the peptide and were discovered by Regoli, 
Riniker and Brunner (1963).
(c) Carboxypeptidases or angiotensinase ’C’: These 
hydrolyse the C-terminal peptide bond and are probably the 
least important of the angiotensinases.
I.3:6 Angiotensin III.
This is a heptapeptide (des Aspl angiotensin II) 
formed by the action of aminopeptidase Al on angiotensin
II. An alternative pathway to its formation has been 
described in the rat (Garcia del Rio, Smellie &
33.
Morton,1981) in which aminopeptidase Al hydrolyses the 
N-terminal aspartic acid of angiotensin I to form des Aspl 
angiotensin I which is then a substrate for converting 
enzyme to form angiotensin III without prior formation of 
angiotensin II. Angiotensin III possesses some residual 
pressor activity (Kono et al.,1975; Carey et al.,1979) and 
was at first thought to be an important steroidogenic 
hormone (Blair-West et al.,1971; Campbell, Brooks & 
Pettinger,1974; Campbell, Schmitz & Itskovitz,1977;
Freeman et al.,1977a). However with the exception of the 
rat (Semple & Morton,1976) the concentration of 
angiotensin III in plasma is small relative to the 
octapeptide (Semple et al.,1976? Carravagi et al.,1976).
1.4 Inhibitors of the renin-angiotensin system.
1.4:1 Structural analogues.
Analogues of angiotensin II which compete for the 
angiotensin II receptor were one of the first groups of 
inhibitors of the renin-angiotensin system to be 
developed. Their conception followed the recognition by 
Bumpus & Smeby (1968) of the initial importance of 
position 8 (phenylalanine) for the biological activity of 
angiotensin II. In 1970, Khairallah,. Toth and Bumpus 
observed that Ala8-angiotensin II blocked the contractile 
response of angiotensin II on the isolated guinea pig
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ileum. Shortly afterwards Ile8-angiotensin II was 
synthesised (Bumpus,1971). However both these analogues 
suffered from poor in vivo activity. This was eventually 
improved by substituting sarcosine at position 1 (Pals et 
al.,1971) which protected the analogue from degradation by 
aminopeptidase A, creating a more effective inhibitor and 
increasing its half life (Bumpus,!977). However all 
inhibitory analogues suffer from the disadvantage, to a 
greater or lesser extent, of residual agonist activity. 
This disadvantage has severely limited the use of such 
inhibitors as investigative tools to study the renin 
angiotensin system. The three most effective inhibitors, 
listed in order of increasing agonist activity are 
Sarl,Ile8-angiotensinII, Sari,Ala8-angiotensin II,
Sari,Thr8-angiotensin II (Bumpus,1977).
1.4:2 Angiotensin converting enzyme inhibitors.
Before 1968, the only known inhibitors of 
angiotensin converting enzyme were nonspecific metal 
chelators such as EDTA. However the key discovery that 
led to the first potent and specific inhibitor of this 
enzyme was published three years earlier. In 1965 
Ferreira showed that an ethanol extract of the Brazilian 
arrowhead viper Bothrops jararaca , potentiated the 
vasodilating effects of bradykinin. In 1966, Ferreira was 
able to show that the activity of the bradykinin 
potentiating factor (BPF) was due to its inhibition of the
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enzymatic degradation of bradykinin by kininases. Soon 
after, Bakhle (1968) reported that the bradykinin 
potentiating factor (BPF) was also a potent inhibitor of 
angiotensin converting enzyme, inhibiting the formation of 
angiotensin II. It was subsequently shown that converting 
enzyme and kininase II were the same enzyme (Yang et 
al.,1970). Up to fifteen active peptides were isolated, 
characterised and eventually synthesised (Ferreira,
Bartlet & Greene,1970; Ondetti et al.,1971). Two of the 
most potent were a pentapeptide (BPF5a) and a nonapeptide 
(SQ 20881, Figure 1.4). BPF5a has a short duration of 
activity in vivo being rapidly broken down by 
peptidases, including converting enzyme. SQ 20881 
(Teprotide) has a much longer half life (1 to 2 hours) and 
while it is an invaluable investigative tool, and shown to 
be effective for the treatment of human hypertension, it 
suffers from the disadvantage that it is active only by 
parenteral administration. To overcome this, orally 
active inhibitors of converting enzyme were
designed and synthesised (Cushman et al.,1977; Ondetti, 
Rubin & Cushman,1977). The design of these orally active 
compounds was based on the known active site of 
carboxypeptidase A, a zinc metallopeptidase thought to be 
similar to converting enzyme. Derivatives of proline were 
chosen as this amino acid is present at the C-terminal 
position of all the venom peptide inhibitors. Of these 
derivatives, 2-D-methyl-3-mercaptopropanoyl-L-proline (SQ 
14225, captopril, Figure 1.4) was found to be the most
Gilu- Trp - Pro - Arg - Pro - Gfn - He - Pro - Pro 
SQ 20881 Teprotide
CH3 O X \  O'
I l ( )  I
HS-CH2 -CH —  C - N — L— C=0  
SQ 14225 Captopril
Figure 1.4 Teprotide and captopril.
potent both in vitro and in vivo . Since the 
development of captopril other orally active inhibitors 
have been synthesised, all of which are based on the 
origional proline model.
One potential disadvantage of captopril as a 
research tool for the investigation of the 
renin-angiotensin system in its regulation of both normal 
blood pressure and hypertension, concerns its specificity. 
Any hypotensive effect it elicits might, in part, result 
from a potentiation of the vasodilator effect of 
bradykinin. However direct evidence for the involvement 
of kinins in the hypotensive effect of captopril is scant, 
principally due to the difficulty of measuring kinin blood 
levels. While McCaa, Hall and McCaa (1978) reported 
increased levels after captopril, Millar & Johnston (1979) 
could find no change. More recent studies have failed to 
detect bradykinin in normal blood (Nielsen et al.,1982) 
suggesting that it is possibly a tissue hormone rather 
than a circulating hormone. Similarly, substantive 
evidence that other extra-renin mechanisms are involved is 
scant. To date, most of its blood pressure lowering 
effects can be explained on the basis of its interaction 
with the renin angiotensin system, the function for which 
it was specifically designed (Cushman et al.,1981).
1.4:3 Renin inhibitors.
Another approach used to inhibit the actions of
the renin angiotensin system has been to synthesise 
peptides which inhibit directly the activity of renin 
itself. In general three methods have been used, all of 
which involve modifying the N-terminal fragment of 
angiotensinogen. The first of these, used by Burton, 
Poulsen and Haber (1975), was to substitute various 
naturally occurring amino acids at different positions in 
the peptide sequence, particularly at positions 10 and 11 
which flank the peptide bond hydrolysed by renin. These 
initial inhibitors had a ki of 3 to 25 uM. However they 
proved ineffective in vivo due to poor solubility at 
physiological pH. Haber (1980) described the decapeptide 
Pro5,PhelO,Phell,Lysl4 angiotensinogen as an effective 
inhibitor of renin in vivo (ki=2uM). The second method 
has been to substitute the unusual amino acid statine at 
position 10 (Boger et al.,1983). Inhibition with ki 
values as low as 27 nM have been obtained by this 
technique. Probably the most effective inhibitors have 
been obtained by the method of Szelke et al. (1982a) in 
which the LeulO/Valll peptide bond is replaced with a 
reduced isostere, that is -CO-NH- is replaced with 
-CH2-NH-. In this way potent inhibitors of both dog 
(ki=20nM) and human (ki=10nM) renin have been obtained 
which are both highly active in vivo (Szelke et 
al.,1982b; Webb et al.,1983). At present renin inhibitors 
suffer from one disadvantage; like angiotensin II 
inhibitory analogues and the early peptide inhibitors of 
converting enzyme, they are active only by parenteral
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administration. However as in the case of converting 
enzyme inhibitors, orally active non-peptide renin 
inhibitors will certainly be developed.
1.5 Experimental renovascular hypertension, historical 
background.
The experimental production of renal hypertension 
is generally considered to date from the definitive 
studies of Goldblatt and colleagues in 1934. By 
constriction of both renal arteries of the dog they were 
able to produce, for the first time, a sustained elevation 
of arterial pressure. In contrast, constriction of one 
renal artery produced only a temporary rise in pressure.
It is from this original work that the two most common 
models of experimental renal hypertension have been 
derived. The first of these is the two-kidney, one clip 
model (2K1C) in which one renal artery (usually the left) 
is constricted by means of a silver clip, while the 
contralateral kidney is untouched. The second is the 
one-kidney, one clip model (1K1C) in which one renal 
artery is constricted and the contralateral kidney is 
removed. Interestingly, there appears to be some species 
difference in the susceptibility of different animals to 
the development of hypertension by these procedures. The 
dog, as demonstrated by Goldblatt, and the rabbit require 
either bilateral artery constriction, or unilateral
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constriction with contralateral nephrectomy to produce 
permanent hypertension. In contrast, the rat (Wilson & 
Byrom,1939) like man, may be rendered hypertensive by 
unilateral constriction only (2K1C).
1.6 Role of renin in renovascular hypertension, acute and 
chronic phases.
These observations rekindled interest in renin and 
its possible involvement in the development of renal 
hypertension of the type described. At the time methods 
for the measurement of circulating renin were not 
generally available and investigators had to rely on 
indirect techniques. These involved removal of the clip 
producing the constriction, removal of the kidney whose 
artery had been clipped, and in the two-kidney, one clip 
model, removal of the contralateral untouched kidney.
Using these techniques, Pickering (1945) was the first to 
suggest that there may be two phases in renal 
hypertension. He demonstrated that removal of a single 
clipped kidney in rabbits (1K1C) produced a fall in blood 
pressure with hypertension of one weeks duration but not 
of eight weeks duration. The two phases were called 
respectively the acute and chronic phases of renal 
hypertension. In addition to this, Byrom & Dodson (1949) 
showed that by removing the clip from the renal artery of 
rats with one-kidney, one clip hypertension blood pressure
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returned to normal regardless of whether they were in the 
acute or chronic stage.
Two conclusions were drawn from these studies. 
Firstly in the one-kidney, one clip model, hypertension 
during the acute stage results from an intrarenal 
mechanism, possibly involving the direct vasoconstrictor 
effect of renin, but that during the chronic stage 
hypertension is maintained by an extrarenal mechanism not 
involving renin and which exists as a consequence of the 
inadequate renal function of the clipped kidney.
Secondly, the cardiovascular changes which occur to 
produce the hypertension in the chronic stage are not 
irreversible.
The effects of such manoeuvres in rats with 
two-kidney, one clip hypertension showed some important 
differences compared to the one-kidney, one clip model. 
While removal of the clip in the acute phase resulted in 
the blood pressure returning to normal (Floyer,1954) this 
was not always the case during the chronic stage (Wilson & 
Byrom,1941; Floyer,1951). Also, subsequent removal of the 
clipped kidney resulted in this residual hypertension 
being sustained at an even higher level. However, if the 
untouched kidney was removed the residual hypertension 
disappeared and the pressure returned to normal. The 
interpretation of these observations was that, as in the 
case of the one-kidney, one clip model, renin from the 
kidney was responsible for the hypertension during the 
acute phase. During the chronic phase however, renin was
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not involved directly and hypertension was maintained by 
an extrarenal mechanism, partly because of an inability of 
the clipped kidney to control blood pressure but also by a 
contributing effect of the opposite untouched kidney. 
Wilson & Byrom (1939) clearly showed that in two-kidney, 
one clip hypertension prolonged exposure to the 
hypertension resulted in the appearance of vascular 
lesions in the untouched kidney and when this occured 
removal of the ischaemic kidney no longer returned the 
blood pressure to normal. It was concluded that the 
damaged untouched kidney contributes to the hypertension 
producing a further rise in pressure which results in 
further progressive damage to the kidney (Byrom &
Dodson,1949). This situation was described by Wilson & 
Byrom (1939) as the vicious circle of hypertension. 
However, Floyer (1954,1957) claimed that such persistant 
hypertension can occur in the presence of an apparently 
normal untouched kidney and before the appearance of 
hypertensive vascular damage. He suggested that renin 
released from the clipped kidney, while insufficient to 
have a direct vasoconstrictor effect, might have, through 
angiotensin II, a localised effect on the opposite kidney 
and inhibit the function concerned with maintaining normal 
blood pressure. This observation and its possible 
explanation has particular relevance to the work presented 
in this thesis.
With the advent of reliable methods for the 
measurement of renin in plasma it became possible to
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examine directly its involvement in renal hypertension.
In one-kidney, one clip hypertension renin levels are 
raised acutely and then fall to normal within a few days 
(Lever & Robertson,1964? Brown et al.,1966? Bianchi, Tilde 
Tenconi & Lucca,1970? Miksche, Miksche & Gross,1970? Liard 
et al.,1974). In two-kidney, one clip hypertension the 
initial rise in renin is followed either by a return to 
normal levels or the presence of a mildly elevated level: 
in the presence of severe or malignant hypertension the 
level is usually elevated (Brown et al.,1966? Blair-West 
et al.,1968? Bianchi et al.,1972? Leenen, DeJong & 
DeWied,1973? Leenen et al.,1975? Liard et al.,1974?
Mohring et al.,1975? Carretero & Gulati,1978). The renin 
content of the clipped kidney is raised and that of the 
contralateral kidney lowered (Miksche et al.,1970; Mohring 
et al.,1975).
The rise in blood pressure during the acute phase 
is almost certainly due to the increase in circulating 
renin and to the direct action of generated angiotensin II 
on the peripheral resistance vessels. The relationship 
between changes in pressure and changes in circulating 
renin and angiotensin II was similar to that seen when 
renin and angiotensin II were infused (Bianchi et 
al.,1970? Cowley, Miller & Guyton,1971? Gutmann et 
al.,1973? Caravaggi et al.,1976). Also treatment with 
angiotensin converting enzyme inhibitors or angiotensin 
receptor antagonists during the acute phase effectively 
prevented the rise in blood pressure (Pals et al.,1971;
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Miller et al.,1972,1975; Thurston & Swales,1974a; Coleman 
& Guyton,1975; Freeman et al.,1977b; Masaki et al.,1977).
During the chronic phase of one-kidney, one clip 
hypertension renin is normal and acute blockade of the 
renin-angiotensin system fails to lower blood pressure 
(Krieger et al.,1971; Bumpus et al.,1973; Romero, Mak & 
Hoobler,1974) unless sodium depletion is induced (Gavras 
et al.,1973). In chronic two-kidney, one clip 
hypertension renin has been reported as being normal or 
slightly elevated and, if in the malignant phase, raised, 
and acute blockade is only partially sucessful in lowering 
blood pressure (Brunner et al.,1971; Krieger et al.,1971; 
Pals et al.,1971; Bumpus et al.,1973; Romero et al.,1974; 
Thurston & Swales,1974a; Carretero & Gulati,1978) unless 
again sodium depletion is induced (Gavras et al.,1975).
These latter studies appeared to confirm the 
original conclusions of Floyer (1951,1957) that the acute 
phase of renal hypertension was renal in origin, acting 
through renin, and that the chronic phase was extrarenal, 
not involving renin.
1.7 Autoregulatory theory of chronic renovascular 
hypertension.
In view of the failure of the acute effects of the 
renin-angiotensin system satisfactorily to account for 
chronic renal hypertension the hypothesis of a volume
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expanded mechanism was advanced (Ledingham,1975). This is 
based on the same homeostatic mechanism as that advanced 
to explain the hypertension seen in partially or 
completely nephrectomised sodium-loaded animals 
(Ledingham,1971). The postulated steps are shown in 
Figure 1.5. Application of a clip to the renal artery 
results in an increase in renin release into the 
circulation. This in turn produces an increase in 
angiotensin II which has a direct vasoconstrictor effect 
and raises blood pressure acutely. Angiotensin II also 
stimulates sodium retention via aldosterone and also 
possibly by a direct intrarenal effect. This results in 
an expansion of extracellular fluid and plasma volume.
This increases cardiac output and leads to tissue 
overperfusion. In response there is local autoregulatory 
vasoconstriction which results in a chronic rise in 
arterial pressure. There will then be a tendency to 
overcome the renal retention of salt and water with the 
eventual restitution of volume homeostasis. Both cardiac 
output and renin will return towards normal. All of this 
is brought about at the expense of a sustained elevation 
of arterial pressure. As propounded by Guyton et al. 
(1972,1975) the fundamental change in the process is a 
resetting upwards of the pressure threshold for renal 
sodium and water excretion. In this view of events the 
renin-angiotensin system is important only during the. 
acute phase when it has a direct action in raising blood 
pressure, and as a pre-requisite for the development of
Direct 
vasoconstriction
Acute rise in 
blood pressure
Renal artery constrictioni
Fall in pressure in renal —  Negative feedback 
artery beyond constriction with restoration of
i sodium and water balance
Increased renin release 
to circulation
i
Increased angiotensin IIi
Increased aldosterone
I
Sodium retention
I
Expansion of extracellular 
fluid volume
Expansion of plasma 
volume i
Increased cardiac output 
\
Tissue overperfusionI
Autoreguiatory vasoconstriction )
Rise in blood pressure------------
iRenin 
Aldosterone 
Cardiac output)
Autoreguiatory
vasoconstriction
Arterial
hypertension
Return to
near
normal
- Persist
Figure 1.5 Postulated sequence of events during the 
development of hypertension after renal 
artery constriction.
the hypertension in the chronic stage, but that during 
this time its direct vasoconsrictor action has no direct 
role in maintaining the hypertension.
Experimental evidence would seem to support such a 
mechanism in one-kidney, one clip hypertension. As 
mentioned, renin is elevated acutely then returns to 
normal. Aldosterone has been shown to be initially, 
transiently elevated (Blair-West et al.,1968; Liard et 
al.,1974). There is a higher than normal exchangable 
sodium (Tobian, Coffee & McCrea,1969; McAreavey et 
al.,1984) and there is initially a positive sodium balance 
(Bianchi et al.,1970; Swales et al.,1972; Liard et 
al.,1974). Cardiac output is also raised initially then 
falls (Bianchi et al.,1970).
Some of the evidence from studies of two-kidney, 
one clip hypertension also fit with a volume expanded 
mechanism but there may be important differences. In 
particular it is by no means certain that there is overt 
sodium retention in this model. Only two studies found a 
positive sodium balance during the early phase (Leenen &
De Jong,1975; Mohring et al.,1975) while most found either 
a negative sodium balance (Blair-West et al.,1968; Swales 
et al.,1972) or no change (Bianchi et al.,1972; Tobian et 
al.,1969; McAreavey, Brown & Robertson,1982; McAreavey et 
al.,1984). Also the extent to which renin returns towards 
normal after the the initial increase is uncertain. This 
uncertainty rises from the variety of methods employed by 
different investigators to study this model. These
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include differences in strain, age and sex of rat, the 
size of clip used and the site at which it was applied to 
produce the stenosis, blood sampling procedures, used to 
measure circulating renin, have also varied and these 
differences have often made it difficult to compare 
results obtained from different laboratories and may go 
some way to explaining some of the contradictory findings 
published in the literature. In view of these differences 
and uncertainties and taking into account the original 
suggestion of Kolff & Page (1955) and Floyer (1957) that 
renin released from the clipped kidney, though 
insufficient to affect blood pressure directly, might 
nontheless have a functional effect on the opposite 
untouched kidney and thereby raise blood pressure by a 
second mechanism, it is conceivable that there may be a 
subtle but important difference in the route by which 
volume homeostasic hypertension is reached in the 
two-kidney, one clip model.
I.8 A possible second effect of angiotensin II on blood 
pressure in two-kidney, one clip hypertension.
The possibility that renin, through angiotensin
II, might contribute to the raised blood pressure in 
renovascular hypertension by a second effect was also 
suggested by Brown et al. (1976). They proposed that 
between the acute and chronic phases there was a second or
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intermediate phase. This intermediate phase was 
characterised by blood pressure being inappropriately high 
for prevailing plasma levels of renin and angiotensin II. 
It was proposed that hypertension during this time was 
maintained principally by a second effect of angiotensin 
II on blood pressure. It was suggested that this might be 
a slowly developing effect which is brought about by 
plasma angiotensin II concentrations below those which are 
acutely vasoconstrictor (Dickinson & Lawrence,1963; 
McCubbin et al.,1965). Studies to investigate the 
possible involvement of such an effect in renovascular 
hypertension have been controversial.. There is good 
evidence that chronic suppression of angiotensin II by 
continuous administration of converting enzyme inhibitors 
teprotide and captopril before and up to 24 weeks after 
application of the clip effectively prevents the 
subsequent development of the hypertension (Freeman et 
al.,1979; DeForrest et al.,1982). However, the ability of 
chronic angiotensin II blockade to lower blood pressure 
after the hypertension has developed is less certain.
Using two-kidney, one clip hypertensive rats, Riegger et 
al. (1977) claimed that chronic infusion of both saralasin 
and teprotide produced an additional significant fall in 
blood pressure and Bengis & Coleman (1979) found arterial 
pressure was restored to normal after 1 week of converting 
enzyme inhibitor administration. However, Bing et al. 
(1981) and Russell et al. (1982) were unable to find any 
additional effect on blood pressure following the chronic
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infusion of either saralasin or captopril.
1.9. The present study.
The purpose of the present study initially was to 
establish a standard and reproducible model of two-kidney, 
one clip hypertension in the rat for use in our 
laboratory. Using this model I proceeded to examine more 
precisely the long-term evolution of two-kidney, one clip 
renovascular hypertension in relation to the changes which 
take place in the renin-angiotensin system. Once this had 
been achieved, the importance or otherwise of renin and 
angiotensin in the development and maintenance of the 
hypertension at different stages was investigated. The 
approach to this latter part of the study was to assess 
not only the the contribution made by the direct acute 
vasoconstrictor effect of the renin system but also to 
examine whether renin, through angiotensin II, exerted a 
second, additional effect on the hypertension. This was 
done by comparing the effect on blood pressure of acutely 
administered inhibitors of converting enzyme with that 
found following their long-term chronic administration.
The whole study was performed in the rat; a small, 
cheap and robust experimental animal which can easily be 
rendered hypertensive in a relatively quantitate way by 
the application of a silver clip to one renal artery, the 
contralateral kidney remaining untouched. Techniques were
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used whereby measurements of blood pressure, plasma renin 
concentration and plasma angiotensin II could be made in 
the conscious and unrestrained animal, thus eliminating 
the effects of anaesthesia and stress.
CHAPTER 2.
MATERIALS AND METHODS.
2.1 Rats.
For all of the studies to be described male 
Sprague Dawley rats were used. These weighed 150-180g and 
were supplied by Olac 1976 Ltd (Bicester, Oxfordshire). 
They ate a standard diet (4IB Oxoid) and drank water ad 
libitum throughout.
2.2 Preparation of renal hypertensive animals.
Rats were made hypertensive by constriction of the 
left renal artery using a silver clip with a 0.2mm 
internal diameter, the right kidney being untouched 
(two-kidney, one clip hypertension).
2.2:1 Construction of renal artery clip.
Clips were constructed from silver ribbon 0.38mm 
by 1.0mm (Johnsson and Matthey Metals Ltd., 43 Hatton 
Garden, London). A.10mm length of silver was cut from 
the strip and the edges were filed until smooth. This 
length was bent round a feeler gauge of appropriate
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thickness (0.2mm) to make one short (4mm) and one long 
(6mm) leg. The end of the longer leg was then bent 
upwards at an angle of 45 degrees to be used for holding 
during application of the clip to the artery. Since this 
may have opened the clip slightly it was then compressed 
again over the feeler gauge, this time using pliers. The 
clips were sterilised in a chlorhexidine/alcohol solution 
and soaked in sterile saline before implantation.
2.2:2 Clipping of renal artery.
Rats were fully anaesthetised with ether which was 
maintained by swab and drop bottle. The abdomen was 
shaved and a 3-5cm incision was made in the midline 
through the skin and the abdominal wall ending at the 
xiphoid cartilage. The exposed gut was displaced to the 
left where it was covered with a saline soaked gauze swab. 
The incision was held open at the right side by rubber 
covered artery forceps and a cotton bud was placed under 
the spleen, pancreas and liver in order to hold them away 
from the area of the left renal artery. This artery was 
chosen to be clipped as it is more accessible than the 
right. The left renal artery was exposed and cleared of 
connective tissue and the clip gently placed across the 
artery just below its junction with the aorta. If the 
kidney blanched the clip was immediatly removed and the 
artery was cleared further before the clip was re-applied. 
The gut was then replaced and the abdominal muscle was
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sutured with surgical silk. The skin was closed either 
with sutures or with 12mm wound clips.
A sham operation was performed on some animals.
The surgical procedure for this was exactly as above 
except that no clip was applied to the artery. In both 
these operations the right kidney was untouched.
2.3 Catheterisation.
Indwelling arterial and venous catheters were 
required for blood pressure measurement, blood sampling 
and for intravenous injections and infusions. For 
short-term experiments a carotid artery catheter was 
implanted, and for long-term experiments requiring 
continuous blood pressure recording and continuous 
infusions, catheters were inserted into the abdominal 
aorta and the inferior vena cava (IVC).
2.3:1 Carotid artery catheters.
(i) Construction of carotid artery catheters.
The form of the carotid catheter is illustrated in 
Figure 2.1. The construction of the carotid catheter and 
the materials used are detailed in Appendix 1.
2.5cm
j Polythene tubing (0.5mm ID, 0.80D)
10cm Tygon (0.5mm ID, 1 .5200)
1cm
1.5cm
Lying within the carotid artery
Figure 2.1 Carotid artery catheter
Materials used and construction are detailed 
in Appendix 1.
(ii) Implantation of a carotid artery catheter.
The catheter was filled with heparin (5000 
units/ml) and the end was plugged. The rat was 
anaesthetised with ether and then shaved at the front and 
the back of the neck. A l-2cm longitudinal incision was 
made at the front of the neck and the left carotid artery 
was freed from the surrounding muscle and nerves by blunt 
dissection. Two lengths of surgical silk were passed 
beneath the artery. The most distal thread from the heart 
was tied in a knot and gentle traction was exerted on this 
tie by artery forceps. The second thread was tied in a 
loose single knot. An aneurism clip was placed as far 
down the exposed part of the carotid artery as possible in 
order to stop the blood flow. Using small sharp scissors 
an incision was made in the side of the carotid artery 
between the clip and the tie. The catheter was inserted 
and moved up until its tip lay against the clip. The 
second tie was knotted more tightly, the clip was removed 
and the catheter was pushed gently into the artery until 
the whole of the polythene tip lay within the vessel. The 
second thread was then tied tightly in a second knot 
around the catheter. One more thread was sewn into the 
underlying muscle and tied securely around the catheter. 
Using a hollow needle, the catheter was then passed 
subcutaneously to the back of the neck where it was 
secured by a suture and was cut to a length which made it 
impossible for the rat to be able to chew it. The front
54.
of the neck was sutured.
On the two days following the operation blood was 
drawn back into a syringe and the dead space of the 
catheter was filled with fresh heparin (5000 units/ml) in 
order to maintain patency.
2.3:2 Aortic and vena caval (IVC) catheters.
(i) Construction of aortic catheter.
This method was modified from the technique of 
Weeks & Jones (1960) (Browning, Ledingham & Pelling,1970; 
Brown,1981). These catheters consisted of four pieces of 
polythene. A, B, C & D, welded together by heating.
Figure 2.2 shows an aortic catheter. The construction of 
these catheters and the materials used are detailed in 
Appendix 2.
(ii) Construction of the IVC catheter.
The IVC catheter also consisted of four pieces of 
polythene sealed together by heating. The materials used 
are identical to those in the aortic catheter construction 
with one exception; for part A, 19cm of polythene was used 
instead of 17cm as used for the aortic catheter. A 
constructed IVC catheter is shown in Figure 2.3. and 
their construction is detailed in Appendix 3.
Heat seals
90° bend here _  
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Anchor point 
Pulled out section
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_ Neck anchor point,
Part A
— Anchor point
Part D
Neck pieci
Figure 2.2 Aortic catheter
Materials used and construction are detailed 
in Appendix 2.
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Materials used and construction are detailed 
in Appendix 3 -
(iii) Testing the catheter.
Both types of catheter, once constructed, were 
tested under pressure for leakage. This was done by 
sealing the end of the catheter and then forcing saline 
into the catheter through a syringe with a filed number 23 
gauge hypodermic needle inserted into the top of the 
catheter. If any leakage occured the catheter was 
discarded.
(iv) Implantation of aortic and IVC catheters.
Catheters were sterilised overnight in a 
chlorhexidine solution. Before implantation they were 
soaked in a sterile saline solution. Rats were 
anaesthetised with Saffan (Glaxovet Ltd, Harefield, 
Oxbridge, England) which was injected intraperitoneally 
(4ml/kg) and the abdomen and the back of the neck were 
shaved and cleaned with the chlorhexidine solution. An 
incision was made along the midline from the pubis to the 
xiphisternum through the skin and the body wall to expose 
the gut. The gut was reflected to the left (rat’s right) 
and covered with sterile saline soaked gauze. The aorta 
and IVC were carefully exposed with the fingers from just 
below the left renal vein to the area of the iliac 
bifurcation. Any fat and connective tissue was removed 
with cotton buds. The left and right psoas muscles were
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also exposed and cleaned and the left lumbar vein and 
artery were freed from the body wall.
The aortic catheter was positioned approximately 
as shown in Figure 2.4 in order to estimate where it 
should enter the psoas muscle. A sharpened guide needle 
was passed through the psoas muscle at this point to the 
subcutaneous tissue of the back. The needle was then 
turned and passed subcutaneously to emerge through the 
skin at the back of the neck between the ears. The neck 
piece of the catheter, with a length of surgical silk tied 
to the anchor point before the S-bend, was fitted onto the 
end of the guide needle. The guide needle, with catheter 
attached, was then pulled carefully through to the back of 
the neck, care being taken not to pull any intra-abdominal 
structures (eg ureter) into the muscles of the posterior 
abdominal wall. At this time the IVC catheter was also 
positioned. The correct entry point in the right psoas 
muscle was identified and the guide needle plus catheter, 
with a length of surgical silk attached to the lower 
anchor point, was passed through the muscle and 
subcutaneous ly to the back of the neck and through the 
hole made for the aortic catheter. Both catheters were 
placed in position so that they lay flat on the posterior 
body wall.
The aortic catheter was secured by sutures to the 
left psoas muscle using the silk already attached. The 
top of the S-bend was passed under the freed left lumbar 
vessels so that the final straight part of the catheter
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Figure 2.4 Position of aortic and vena caval catheters.
was lying on top of the aorta and parallel to it (Fig
2.4). The anchor point on the S-bend was then secured to 
the underlying muscle with surgical silk. The catheter 
tip was trimmed to a bevel of about 45 degrees at a point 
5-10mm above the aortic bifurcation. A 1ml syringe with a 
filed down number 23 gauge hypodermic needle was filled 
with saline and attached to a 30cm length of polythene 
tubing (ID 0.58mm, OD 0.96mm). This was connected to the 
end of the catheter by 2cm of needle tubing (number 23 
gauge). The catheter, now filled with saline, was ready 
to be inserted.
The aorta was occluded with the finger above the 
level of the renal arteries. Using a number 25 gauge 
sterile hypodermic needle a hole was made in the aorta 
approximately 5mm below the level of the left renal 
vessels. The needle used to pierce the aorta had 
previously been bent to a right angle about 3mm from the 
tip so that there was less possibility of the needle 
piercing the posterior wall of the aorta. The needle was 
removed and the free end of the catheter inserted through 
the hole into the aorta and gently fed down the vessel.
The occlusion on the aorta was released slowly and if any 
bleeding occured through the site of insertion pressure 
was maintained until a clot had formed. In practice there 
was little bleeding. A small ammount of saline was 
squirted into the catheter to clear any blood out of it. 
The neck end of the catheter was then clamped with artery 
forceps, the length of polythene tubing with syringe
attached was removed, and the catheter was plugged with a 
1cm length of stainless steel wire (0.7mm diameter) which 
had been filed smooth at the ends to prevent damage to the 
catheter.
The syringe and polythene tubing were then 
connected to the IVC catheter. The tip of this catheter 
was trimmed straight across to 5cm. The catheter was 
gently pulled back through the muscle from the neck until 
the tip was lying just above the bifurcation of the IVC. 
The tip of the catheter was then used to pierce a hole in 
the IVC at its bifurcation and the catheter was pulled 
gently at the back of the neck until the whole of the tip 
lay inside the IVC and the A-D seal (see Appendix 3) lay 
against the hole in the bifurcation. The silk attached to 
the anchor point on part A was sutured into the muscle and 
a small ammoumt of saline was injected through the 
catheter in order to remove any blood. The syringe and 
tubing were removed and the catheter was plugged. The gut 
was then replaced, the abdominal muscle sutured and the 
skin closed with 12mm wound clips.
At the back of the neck, the skin was incised 
longitudinally from the point of exteriorisation of the 
catheters until the neck anchor points on the catheters 
were exposed, usually 15 to 20mm. Sutures were tied 
around these anchor points and sewn into the muscles of 
the neck in order to prevent the catheters being pulled 
out. Second sutures were tied around the 90 degree bends 
in the catheters and these too were sewn into the
musculature. The skin was sutured and the rats were given 
ampicillin (170ug) subcutaneously. On the day after 
implantation blood was drawn up the arterial catheter and 
the dead space was filled with 0.04ml sodium heparin (1000 
units/ml) which was replaced twice daily during the 
experiment to maintain patency. The venous catheter was 
filled with 0.04ml saline containing sodium heparin (150 
units/ml).
2.4 Experimental cages.
Before the catheters were implanted rats were 
housed in groups of four in plastic cages with aluminium 
lids in an animal house of constant temperature (18-22C) 
and lighting (12 hour light/darkness cycle). Following 
catheterisation they were housed individually in these 
cages for a period of recovery.
2.4:1 Short-term studies.
During the short-term experiments, in which 
carotid artery catheters had been implanted, rats were 
placed in cylindrical polycarbonate cages which were 
32.5cm high and 21.5cm in diameter. These cages were 
fitted with a lid which had an 8cm hole cut in the centre. 
The floor of the cage was covered with a layer of sawdust. 
A 45cm extension of polythene tubing (ID 0.58mm, OD
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0.96mm) filled with saline was connected to the carotid 
catheter with a 2cm length of filed 23 gauge needle 
tubing. This extension was protected by a 30cm length of 
polythene tubing (200/490/060 Portex ID) which fitted 
snugly over the end of the carotid catheter. This 
protective tubing containing the catheter was held upright 
by means of a fine nylon line connected to a horizontally 
free running swivel which in turn was attached to another 
length of line which was fed over a vertically free 
running pulley wheel fixed above the cage and by means of 
a small lead weight tied to the end of the line (see 
Figure 2.5). This swivel and weighted line allowed free 
movement of the rat in all directions and prevented 
tangling of the extended catheter, which in turn had been 
connected by another length of polythene (2.5m, ID 0.58mm, 
OD 0.96mm) to the blood pressure recorder (see Figure
2.5). The maximum ammount of time the rats spent in these 
cages never exceeded 3 hours.
2.4:2 Long-term studies.
For these experiments, aortic and IVC catheters 
were implanted. After a period of recovery in their 
normal cages rats were transferred to modified metabolic 
cages (Techniplast (R), Forth-Tech Services Ltd.
Midlothian, Scotland) (Figure 2.5). These cages allowed 
the rats free access to food and water, but as a metabolic 
balance study was not being carried out, the metal grid on
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Figure 2.5 Experimental cage for long-term studies.
The same nylon line and swivel system was 
used in the short-term studies using a 
carotid catheter.
the floor of the cage was covered with a metal plate upon 
which a layer of shavings was spread. A 10cm length of 
perspex cylinder was added to the top of the standard cage 
to raise its height to 26cm. This allowed the rat to 
stand on its hind legs and just reach the upper rim. The 
cage was closed by a perspex lid with a 5cm hole in its 
centre.
Polythene tubing extensions (45cm) were connected 
to the aortic and IVC catheters as described for the 
carotid artery catheter. These were filled with 130ul of 
sodium heparin (1000 units/ml) and heparin/saline (150 
units/ml) respectively and when not in use for blood 
pressure measurements or intravenous infusions were 
plugged with stainless steel plugs. The extensions were 
protected by a 30cm long flexible but tightly wound steel 
spring (0.2cm ID). A 3cm length of silastic tubing was 
fixed over the end of the spring and fitted snugly over 
the connections to lie flush with the neck of the rat and 
serve to protect the catheters at a potentially vulnerable 
point. The other end of the spring was held upright by 
the same swivel and nylon line system as described for the 
carotid artery catheter.
2.5 Blood pressure measurement.
2.5:1 Measurement of arterial pressure.
Arterial catheters were connected to Elcomatic EM
751 transducers via a length of polythene tubing (2.5m, ID
0.58mm, OD 0.96mm) and filed number 23 gauge needle
amplifier and
tubing. The transducer was connected to an EM720Apen 
recorder (Elcomatic, Kirktonfield Road, Neilston, Glasgow 
G78 3PL) which was calibrated weekly against a standard 
mercury manometer. In the first experiment, where blood 
pressure recording lasted no longer than 2.5 hours, blood 
pressures were calculated by hand from the recorder chart 
as the average of 5 minute interval readings of the mean 
pressure (diastolic plus one third of the pulse pressure) 
for the last 1 hour of recording. In Experiment 2, where 
blood pressure was recorded continuously for 9 days an 
Apple lie microcomputer was connected via an Al-02 
analogue/digital interface (Interactive Structures, Bala 
Cynwyd, USA) to the voltage output of two Elcomatic 
recorder amplifiers. A pressure range of 0-250 mmHg 
produced a voltage range from the amplifier of 0 to 2.5 
volts. This was converted by the interface to a digital 
range of 0 to 128. Before the start of and every 2 days 
during the experiment each of the 4 amplifier chart 
recorders and the equivalent computer channels were 
calibrated simultaneously over the range 0 to 250mmHg 
using an external pressure standard given by a mercury
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manometer. A linear relationship between standard 
pressure and digital output was obtained for each channel 
and a channel calibration factor calculated. The 
calibration factor for each channel was entered in the 
basic programme as a variable and was used to convert 
digital output to millimeters of mercury pressure before 
storage on the disk.
A programme was written in basic which allowed 
arterial pressure to be sampled and stored at a minimum 
time interval of one minute. Each rat was sampled 
sequentially and the mean pressure on each occasion was 
calculated by the programme to be the mean of 200 separate 
digital measurements taken over a maximum period of 2 
seconds. Each of these 200 measurements would be taken at 
random over approximately 10 pulse waves. Thus the mean 
value multiplied by the calibration factor would be an 
accurate estimate of the mean pressure; defined as the 
diastolic plus half the pulse pressure. After sampling 
all four rats, the time of sampling, the rats' numbers and 
their mean arterial pressures were stored in random access 
files on disk. The programme was also able to identify 
incorrect pressures due to the blocking of catheters. To 
do this, the pulse pressure from the 200 separate 
measurements was calculated and if this was less than a 
stated value then the mean blood pressure recorded was 
indicated as having been obtained from a damped pulse.
The programme also allowed temporary interruption of blood 
pressure monitoring which allowed catheters to be cleared
and the system to be recalibrate^ ^  at any time all or 
part of the stored data to be produced as a hard copy. A 
mean value of any number of sequentially stored pressure 
measurements for any rat could also be calculated and this 
could be stored in a separate file on disk.
2.5:2 Measurement of heart rate.
Heart rate was measured during the recording of 
arterial pressure by speeding up the trace until 
individual pulse waves were visible and countable. The 
number of pulse waves in a 5 second interval were counted 
and this was multiplied by 12 to give the heart rate in 
beats per minute.
2.5:3 Measurement of systolic blood pressure.
Systolic blood pressure was measured by tail 
plethysmography using a W & W 8005 recorder (W and W 
Electronic Instruments, CH-4002 Basel, Munchenstein, 
Switzerland). The rat was warmed in an incubator at 37C 
for 15-20 minutes to ensure vasodilation. When it was 
removed it was lightly restrained by wrapping in a towel 
with its tail protruding and the pressure cuff was pushed 
over the tail up to the root followed by the pulse 
detector. Six readings were taken within 2 minutes and 
the blood pressure was calculated as the mean of the last 
4 readings.
2.6 Continuous intravenous infusion.
Continuous intravenous infusion was given by an 
infusion pump (Dascon IP 300, Uden, The Netherlands) which 
had a variable flow rate. For all the experiments 
described the infusion rate was 1.0ml/24 hours. The pump 
was modified to take a 5ml syringe and was recalibrated 
for this. The syringe was connected by means of a filed 
number 23 gauge hypodermic needle to a length of tygon 
tubing (ID 0.5mm, OD 1.52mm, Norton Plastics, Akron ,
Ohio). This in turn was connected to the end of the 
venous catheter extension via a 2cm length of number 23 
gauge needle tubing.
2.6:1 Captopril.
Captopril was supplied by Squibb Europe Inc. 
(Hounslow, Middlesex) in powder form which was stored in 
an air tight, moisture free container at -20C. When 
required as infusate it was dissolved in 5% dextrose 
containing heparin (150 units/ml).
2.7 Injections.
During the short term experiments injections of 
angiotensin converting enzyme nonapeptide (teprotide) were 
given via the carotid catheter.
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2.7:1 Teprotide.
The teprotide was supplied by Beckman, (High 
Wycombe, Buckinghamshire). It was dissolved in saline 
(154mmol/l) at a concentration of lmg teprotide /kg rat in 
0.1ml saline. The catheter was disconnected from the 
transducer and the blood was drawn back to the top of the 
extension line. The material was then injected slowly 
down this line followed by 0.25ml saline. The catheter 
was then reconnected to the blood pressure transducer.
In the long term experiments, in which aortic and 
IVC catheters had been implanted, the rats received bolus 
injections of angiotensin I and of captopril.
2.7:2 Angiotensin I.
Angiotensin I was supplied by Cambridge Research 
Biochemicals Limited (Harston, Cambridgeshire) and was 
dissolved in saline at a concentration of lOOpg/ml saline. 
This was frozen in aliquots and stored at -20C until used. 
When required for injection this was thawed and diluted to 
a concentration of lOOng/O.lml saline. Injections of 
0.1ml angiotensin I solution were used as a test of the 
effectiveness of the angiotensin converting inhibitor 
(captopril) to inhibit angiotensin converting enzyme 
activity and hence block the formation of angiotensin II,
2.7:3 Captopril.
Captopril for injections was diluted in 0.9% 
saline at a concentration of 2.5mg/kg rat in 0.1ml saline.
Before infusions were started the venous catheter 
was used as the route for injections. The material was 
injected straight into the venous line followed by 0.25ml 
heparin saline (150 units/ml). As an immediate pressor 
response is seen after injection with angiotensin I this 
proved useful as a test of the patency of the venous 
catheter as it is not always possible to draw blood back 
up the catheter even though it lies inside the vein.
Once the rats were being infused, injections were 
given via the aortic catheter. Blood was drawn to the end 
of the aortic catheter extension line, as for the carotid 
catheters, and after the injection followed by saline, the 
catheter and line were filled with 0.17ml of fresh heparin 
(1000 units/ml) and reconnected to the transducer.
2.8 Blood sampling.
For angiotensin II and renin measurements 0.75ml 
blood was drawn rapidly from the arterial line into an ice 
cold syringe containing 0.075ml of an aqueous solution of 
0.1M ethylenediaminetetra-acetic acid (disodium salt) and 
0.05M o-phenanthroline and were immediatly chilled in ice. 
This solution completely inhibits rat plasma converting
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enzyme and angiotensinases and is used with arterial blood 
in a ratio of 1:10. Blood samples were centrifuged as 
soon as possible at 5°C and 1400g for 20 minutes and the 
plasma was stored at -20°C until extracted.
For angiotensin converting enzyme estimation 0.1ml 
of arterial blood was drawn rapidly into a heparinised 
syringe. All converting enzyme assays were performed less 
than 5 hours after the samples were taken as it has been 
shown that angiotensin converting enzyme activity 
increases with storage time in plasma samples containing 
captopril (Roulston & MacGregor,1980).
0.05ml of blood was drawn into a heparinised 
capillary tube for haematocrit measurement.
At the end of experiments rats were killed by 
either an intravenous or intra-arterial injection of 
pentobarbitone sodium (Sagatal, May & Baker Ltd,
Dagenham).
2.8:1 Measurement of plasma angiotensin II.
Angiotensin II immunoactive material was extracted 
from plasma by the addition of sodium chloride solution 
(154mmol/l: saline; 5ml), followed by mixing for 1 hour in 
batches with Dowex resin (50-100 mesh, H+, 400mg; Bio-Rad, 
Richmond, CA, USA) at 4°C. The plasma supernatant was 
sucked off and the Dowex, containing the extracted 
angiotensin II was washed with two volumes of distilled
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water (5ml) followed by two volumes of methyl alcohol 
(5ml). Elution of angiotensin II was achieved by mixing 
the Dowex with 10% methanolic ammonia (2ml) for 30 
minutes. The tubes were centrifuged and the 2ml 
supernatants were removed. These extracts were then dried 
in a water bath at 37C under a stream of air. The dried 
extracts were stored at -20C until assayed, when they were 
dissolved in 0.05M Tris pH 7.5. For the radioimmunoassay, 
0.1ml of extract were incubated with 0.1ml angiotensin II 
antiserum (9/P) at a dilution of 1:20,000, and 50j j l1 of 
1251-labelled angiotensin II (2pg). Duplicate standard 
curves from 0 to 50 pg were set up. Incubations were
o
carried out for 18 hours at 5C. The separation of 
antibody-bound from free labelled angiotensin II was 
achieved using dextran coated charcoal. One ml of the 
charcoal suspension was added to each tube, mixed rapidly 
and centrifuged at lOOOg for 7 minutes at 5°C. The 
supernatant, containing the bound labelled angiotensin II, 
was aspirated with a water pump and discarded. The 
radioactivity of the free label adsorbed to the charcoal 
pellet was then counted in an automatic gamma-ray counter. 
The interassay coefficient of variation for the assay is 
13.6% and it is capable of detecting as little as 0.5 fmol 
of angiotensin II; that is 7 fmol/ml of plasma for a 
0.25ml sample corrected for a recovery of 84% and a 1:3 
dilution. For further details see Dusterdieck & McElwee 
(1971) and Garcia Del Rio et al. (1981).
2.8:2 Measurement of plasma renin concentration.
The method for the measurement of plasma renin 
concentration was a modification of the antibody trapping 
method of Poulsen & Jorgensen (1974) as published for 
human blood by Millar et al. (1980). The enzyme 
incubation and antibody trapping procedure was as follows. 
Duplicate rat plasma samples (3|il) were incubated at 0°C
o
and at 37C for 5, 30 or 60 minutes, depending on the renin 
content, with a mixture (14|il) containing angiotensin I 
antiserum (981/7) diluted 1:80 in 3M Tris/HCl pH 7.0, and 
rat renin substrate in a ratio of 1:6. The enzyme 
incubation was stopped by rapidly cooling the samples in 
ice-water. The angiotensin I generated and trapped was 
estimated in the same tube by radioimmunoassay as follows. 
Cold 0.05M Tris/HCl, pH 7.5 (0.3ml) was added to each 
sample, followed by 10 pg of 1251-labelled angiotensin I 
(in 0.05ml of Tris, pH 7.5). This gave a final 
radioimmunoassay antibody dilution of 1:14680 in a final 
volume of 0.367ml. The samples were incubated at 5C for 
18 hours, after which time the bound and free labelled 
angiotensin I were separated as previously described by 
the addition of plasma coated charcoal (Millar et 
al.,1980). Duplicate standard curves (1.6-200pg) were 
subjected to exactly the same procedures as the unknown 
plasma samples.
Rat renin substrate was prepared by bleeding rats 
which had been bi-nephrectomised 24 hours previously and
which had been given a subcutaneous injection of long 
acting polyestradiol phosphate (Estradurin, Lunbeck,
Luton, UK) 10 days before nephrectomy (Nasjletti,
Matsunaga & Masson,1969). This substrate preparation was 
shown to be completely free of renin and sufficient was 
added to the enzyme incubation to ensure zero-order 
kinetics.
Estimation of the above modifications showed that 
the pH of the enzyme incubation was stable at 7.0-7.2 for 
up to 24 hours at 37°C. Also, the initial trapping 
dilution of the angiotensin I antibody (1:80) was shown to 
be well in excess of that required over the range of the 
standard curve used. The limit of detection of the assay 
was as little as 4.0 fmol of angiotensin I; that is a 
plasma renin concentration of as low as 1-1.5 pmol of 
angiotensin I/ml/hour for a 3pl plasma sample incubated 
for 1 hour. The between assay coefficient of variation 
was +/- 14.6%
2.8:3 Measurement of plasma angiotensin converting 
enzyme.
Plasma angiotensin converting enzyme was measured 
by a slight modification of the spectrophotometric method 
of Cushman & Cheung (1971b) with a
hippuryl-histidyl-leucine substrate (Sigma, Poole, Dorset) 
and 0.025ml plasma samples. For each plasma sample 
duplicate blank and test incubations were set up in glass
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test tubes as follows. 0.075ml of saline (154mM) was 
added to 0.025ml of plasma and this was incubated at 37C 
for 60 minutes with lOOpl of 12.5mM
hippuryl-histidyl-leucine in 400mM potassium phosphate, pH
8.3, and 600mM sodium chloride. Blank tubes also
contained 0.25ml 1M HCl at this stage. The reaction in
the test incubations was stopped after 1 hour by the
addition of 250p.l 1M HCl. Ethyl acetate (1.5ml) was then
added to all tubes and the samples were extracted by
vortexing for 15 seconds. After centrifugation for 10
minutes at 1400g, 1ml of the supernatant was removed into
o
a glass tube and dried m  a water bath at 37C under an air 
stream. The dried extract was dissolved in 1ml of 
distilled water by mixing vigorously. The optical density 
of the samples was then read on a spectrophotometer at a 
wavelength of 228nm and the concentration of angiotensin 
converting enzyme in pmoles/ml/h was calculated from a 
standard curve of hippuric aciot.
2.9 Statistical methods.
Mean values were tested for significant 
differences by Students t-test for paired or unpaired 
observations. Correlations between two variables were 
tested by linear regression analysis and the slopes of the 
regression lines were compared using a common slope 
regression test (f-test) based on analysis of variance. A
one-tailed Wilcoxon signed-ranks test for matched pairs 
was used in the second experiment to compare mean blood 
pressures after chronic captopril infusion with the lowest 
blood pressure seen after an acute captopril injection.
All values quoted throughout are mean .+/- standard 
deviation.
CHAPTER 3
CHANGES IN RENIN AND ANGIOTENSIN II DURING THE DEVELOPMENT 
OF TWO-KIDNEY, ONE CLIP HYPERTENSION IN THE RAT AND THE 
EFFECT OF ACUTE ADMINISTRATION OF CONVERTING ENZYME 
INHIBITOR.
3.1 Introduction.
The model of the two-kidney, one clip Goldblatt 
rat was first demonstrated by Wilson and Byrom in 1939. 
Since this time the involvement of renin and angiotensin 
in this model has been extensively studied. From studies 
using a number of different species it has been suggested 
that immediatly after the application of the clip plasma 
renin rises (Brown et al.,1966? Blair-West et al.,1968; 
Bianchi et al.,1972; Liard et al.,1974; Carretero & 
Gulati,1978) and is probably responsible for the 
hypertension which develops during this acute phase 
(Bianchi et al.,1968; Pals et al.,1971; Thurston &
Swales,1974a; Coleman & Guyton,1975; Miller et al.,1975; 
Caravaggi et al.,1976; Freeman et al.,1977b; Masaki et 
al.,1977; Carretero & Gulati,1978). However the 
involvement of the renin angiotensin system in the 
development and maintenance of the hypertension after this 
acute phase is less certain. Much of this uncertainty may 
be due to the different methods used by different
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investigators. These include using rats of different 
strain, sex and age, and different sizes of clips or 
ligatures placed at different sites along the renal 
artery, both of which may influence the rate of 
development and the severity of the hypertension (Leenen & 
Myers,1984). Various methods of blood sampling have also 
been used, for example sampling from indwelling catheters 
in conscious rats (Riegger et al.,1977; Otsuka et 
al.,1979), decapitation (Leenen & DeJong,1975; Ten Berg, 
Leenen & DeJong,1979), and sampling under ether 
anaesthesia (Mohring et al., 197.5; Sen et al.,1979; 
Thurston, Bing & Swales,1980), ether being a well known 
stimulus of renin secretion (Leenen & DeJong,1975). These 
differences in technique make the comparison of results 
between laboratories difficult.
The purpose here was to set up a reproducible 
experimental model in our laboratory and using this to 
follow the changes which took place in the 
renin-angiotensin system and to determine the importance 
of such changes in the regulation of the hypertension 
which develops.
3.2 EXPERIMENT 1(a).
A study of the changes in blood pressure, angiotensin II 
and plasma renin concentration during the developement of 
two kidney one-clip hypertension in the rat.
3.2:1 Experimental design.
Groups of up to 30 rats were operated on at any 
one time. These were either clipped or sham-operated 
(2.2:2) in pairs alternately. Rats were selected at 
random and a carotid artery catheter was inserted, as 
previously described (2.3:1), at one of the following 
times: 1 and 2 days after clipping, at weekly intervals up 
to 10 weeks and at 15 weeks and 20 weeks. The 1 and 2 day 
rats had their catheter implanted at the same time as the 
renal artery was clipped. On the second day after 
implantation of the catheter rats were placed in 
cylindrical polycarbonate cages and connected via their 
carotid catheter and the pressure transducer to the blood 
pressure recorder. The rats were allowed to settle for 30 
minutes after which their blood pressure was recorded 
directly and continuously for 1.5 hours. At the end of 
this time heart rate was measured and blood rapidly 
removed via the carotid catheter for the measurement of 
angiotensin II, plasma renin concentration and packed cell 
volume (0.85ml total). Rats were then either studied 
further (see 3.3) or killed by an intra-arterial injection 
of pentobarbitone sodium. Blood pressure was calculated
as the average of 5 minute interval readings of the mean 
pressure (diastolic plus one third of the pulse pressure) 
for the last one hour of recording. All values quoted are 
mean +/- standard deviation.
3.2:2 Results.
(i) Number of rats studied.
A total of 199 rats were clipped but of these 40 
either died or were killed by intraperitoneally 
administered pentobarbitone sodium because they appeared 
unwell. These rats all died or were killed between 4 and 
20 weeks after clipping, the majority (58%) dying between 
6 and 9 weeks, and 90% having died by 13 weeks. The 
remaining 159 clipped rats and the 134 rats which had been 
sham-operated were randomly allocated into groups as shown 
in Table 3.1. Each group contained between 7 and 11 rats.
As the results from the 1 day and 2 day rats were similar
these were combined to give one group of 21 rats. The 4 
week clipped group was chosen to be studied further with 
the administration of converting enzyme inhibitor and so 
extra rats were included. The results from 9 rats were 
not included in the analysis, 3 of these were from the 14
rats in the 15 week group and 6 were from the 14 rats in
the 20 week group. The reason for their exclusion was 
that since 90% of the rats that died did so within 13 
weeks of clipping, it was difficult to obtain rats with
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Group Clipped rats 
No.
Sham operated rats 
No.
1-2 days 21 21
1 week 10 9
2 weeks 9 10
3 weeks 9 8
4 weeks 21 7
5 weeks 10 10
6 weeks 11 9
7 weeks 9 10
8 weeks 11 11
9 weeks 10 9
10 weeks 10 10
15 weeks 11(14) 10
20 weeks 8(14) 10
150(159) 134
Table 3.1 Groups of rats studied.
severe hypertension at 15 and 20 weeks as a large 
proportion of the rats which survived to this time were 
only mildly or moderately hypertensive. Therefore because 
these rats were only moderately hypertensive compared to 
the rest of the rats in their groups they were excluded. 
This allowed a comparison of angiotensin II and plasma 
renin concentrations in the 15 and 20 week late chronic
rats with those found for the 8 to 10 week early chronic
rats where the severity of the hypertension was similar
for both. In all other groups the results from all rats
studied in each group were included in the analysis 
whether the rats were normotensive, mildly hypertensive or 
severely hypertensive.
/
(ii) Changes in blood pressure.
Figure 3 .1(i) shows the blood pressures of the 
clipped and sham-operated rats up to 20 weeks after 
operation. There were no detectable differences between 
the blood pressures of any groups of sham-operated rats, 
the mean blood pressure for all sham-operated rats being 
107 +/- 12.3 mmHg, n= 132. For the clipped rats blood 
pressure was elevated at 1 and 2 days after clipping 
compared to the pressures in the equivalent sham-operated 
group. Pressures in the clipped rats remained at this 
elevated level for up to 2 weeks after which there was a 
progressive rise in pressure which reached a plateau at 5 
to 6 weeks. From 5-6 weeks to 20 weeks after clipping
79.
200
BP 
(mmHg)
150 -
100
150 -
PRC 
(pmol h“ ^
ml-1) 100 -
50 -
200-
ANG.II
(fmol m l-1  150 -  
plasma)
100-
(iii)
5 0 -
"l
20
T
4
T
5
T
6
i r
7 8
t r
9 10
x
3
T —
15
i i r
1+2 1 2
Days WEEKS AFTER CLIPPING
Figure 3.1 Changes in blood pressure (BP) (i), plasma
renin concentration (PRC) (ii) and angiotensin 
II (ANG.II) (iii) in two-kidney, one clip 
hypertensive (•) and sham-operated rats (O)
1-2 days, at weekly intervals up to 10 weeks 
and at 15 and 20 weeks after operation. Bars show 
+/- SEM. Significant differences (unpaired 
t-test) are related to the equivalent group of 
sham-operated rats: **** p<0.001; *** p<0.01:
** p<0.02; * p<0.05.
this hypertension was sustained with average mean 
pressures ranging between 150-179 mmHg. If the 9 rats 
from the 15 and 20 week groups which were excluded from 
this analysis had been included , then a reduced blood 
pressure at 15 and 20 weeks of 167 +/- 27.3 and 144 +/-
28.6 mmHg respectively would be seen (instead of 176.9 +/-
20.6 and 173.1 +/- 12.6)
In a separate experiment systolic blood pressure 
was measured sequentially by tail plethysmography in 14 
rats, 8 clipped and 6 sham-operated at various stages 
after clipping. The results from the clipped rats in this 
longitudional study are shown in Figure 3.2. This 
sequential rise in pressure was very similar to that found 
for the individual groups of rats in the main cross 
sectional study. The mean systolic pressure for the 6 
sham-operated rats was 143 +/- 8.2 mmHg.
(iii) Changes in angiotensin II and plasma renin 
concentration.
x
The plasma renin and angiotensin II 
concentrations for the groups of clipped and sham-operated 
rats at the different stages up to 20 weeks after 
operation are shown in Figure 3.1(ii) and (iii). In the 
clipped group both angiotensin II and plasma renin 
concentrations were significantly increased at 1-2 days 
compared with the group of sham-operated rats (89.7 +/-
8.9 and 24.6 +/- 4.9 respectively, compared with 54.3 +/-
80.
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5.5 fmol/ml and 12.3 +/- 2.0 pmol Angl/ml/h) . Following 
this, concentrations of both fell to reach their lowest 
values at 2 weeks, 43.0 +/- 11.8 fmol/ml for angiotensin 
II and 6.5 +/- 4.0 pmol Angl/ml/h for plasma renin 
compared to 40.5 +/- 2.9 and 3.5 +/-0.6 respectively for 
the sham-operated group. At 2, 3 and 4 weeks angiotensin 
II levels were significantly lower than at 1-2 days (p < 
0.01, 0.05 and 0.1 respectively) and were not 
significantly different from the 2, 3 and 4 week groups of 
sham-operated rats. Plasma renin levels were also lower 
at 2, 3 and 4 weeks than at 1-2 days, this difference only 
being significant at 2 weeks (p < 0.05) and only at 2 and 
3 weeks was there no significant difference from the 
equivalent sham-operated groups.
It is interesting to note that at 3 and 4 weeks, 
when the angiotensin II levels were significantly lower 
than at 1-2 days, the blood pressure was rising, and at 
both 3 and 4 weeks was significantly higher than at 1-2 
days (p < 0.05 and 0.001 respectively).
After 5 weeks both angiotensin II and plasma renin 
concentrations increased again reaching a maximum at 8 
weeks. This increase remained significant up to 20 weeks 
after clipping, the mean values ranging between 109-176 
fmol/ml for angiotensin II and 99-153 pmol Angl/ml/h for 
plasma renin.
For all clipped rats there was a highly 
significant correlation between blood pressure and log 
angiotensin II concentration (r = 0.68, p < 0.001, n =
81.
140) (Figure 3.3), and also between blood pressure and log 
plasma renin concentration (r = 0.70, p < 0.001, n = 145). 
In the sham-operated rats there was no detectable 
relationship between blood pressure and either angiotensin 
II or plasma renin concentration.
If the 6 rats excluded from the 20 week group had 
been included then the plasma angiotensin II and plasma 
renin levels for this group would be lower, 82.7 +/-85.4 
fmol/ml instead of 139.6 +/- 106.9 and 69.5 +/- 105.9 pmol 
Angl/ml/h instead of 146.1 +/- 125.5 respectively.
(iv) Changes in body weight.
The mean body weight at the time of operation was 
180 +/- 14.4 g for all clipped rats and 183.9 +/- 17.0 g 
for all sham-operated rats. After a small decrease in 
body weight immediatly after clipping both clipped and 
sham-operated rats gained weight at the same rate from 1 
week to 4-5 weeks. After this time the clipped rats did 
not grow as rapidly as the sham-operated rats and were 
significantly lighter at 8, 9, 10 and 20 weeks. At 15 
weeks although the clipped rats were lighter the 
difference from the sham-operated rats was not 
statistically significant. Figure 3.4 (i) shows the 
changes in body weight.
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Figure 3.3 Correlation between mean blood pressures and 
log angiotensin II for all clipped rats.
(v) Changes in packed cell volume.
There was no significant difference in packed cell 
volume between the clipped rats and the sham-operated rats 
at any time (Figure '3.4(H))
(vi) Changes in heart rate.
There was no significant difference in heart rate 
between the clipped and sham-operated rats at any time 
(Figure 3.4 (iii)), however as they grew older both 
clipped and sham-operated rats showed a significant 
reduction in heart rate compared with the 1 week values, 
this first being evident at 6 weeks.
(vii) Angiotensin II / blood pressure regression lines.
Relationships between angiotensin II concentration 
and blood pressure were tested for 3 groups of clipped 
rats at the 3 different stages in the development of the 
hypertension as defined from Figure 3.1. The first of 
these stages is the acute stage where both the blood 
pressure and the angiotensin II are elevated. The group 
of rats representing this stage consisted of the 1-2 day 
clipped rats. The second stage is the intermediate stage 
in which blood pressure is rising further but the 
angiotensin II is suppressed. The 3 and 4 week rats
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Figure 3.4 Changes in body weight (i), packed cell volume 
(haematocrit) (ii) and heart rate (iii) in 
two-kidney, one clip hypertensive (•) and 
sham-operated (O) rats, 1-2 days, at weekly 
intervals up to 10 weeks and at i5 and 20 
weeks after operation. Bars show +/- SEM.
With the exception of heart rate significant 
differences (unpaired t-test) are related to 
the equivalent group of sham-operated rats.
For heart rate significant differences (paired 
t-test) for both clipped and sham-operated 
rats are related to the equivalent values at 
1 week after operation: **** p<0.001; *** 
p<0.01; ** p<0.02; * p<0.05.
represented this stage. The final stage is the chronic 
stage where the hypertension has become established and 
the angiotensin II is again elevated. This group 
consisted of the 8 to 20 week rats.
A relationship between the blood pressure and the 
angiotensin II concentration was found for the 1-2 day 
rats in the acute phase (r= 0.48, p< 0.05) and for the 
8-20 week rats in the chronic phase (r= 0.51, p< 0.001), 
but no relationship was found for the rats in the 
intermediate phase (3 and 4 week rats). Figure 3.5 shows 
the regression lines for the acute and chronic phase 
clipped rats. Although there was no difference in the 
slope of the regression lines for both groups (a given 
concentration of angiotensin II being associated with the 
same change, in blood pressure for both groups) it can be 
seen that the regression line for the rats in the chronic 
phase has been shifted upwards in a parallel fashion. The 
fact that these lines are parallel suggests that the rats 
in the chronic phase of the hypertension have the same net 
vascular responsiveness to the acute effects of endogenous 
angiotensin II as the rats in the acute phase, 1-2 days 
after clipping. The upward shift seen in the regression 
line for the chronic phase rats suggests that some 
mechanism other than the acute effect of angiotensin II is 
responsible for the greater part of the hypertension in 
the chronic phase.
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Figure 3.5 Angiotensin II/blood pressure regression 
lines for acute(l-2 days, X) and chronic 
(8-20 weeks, •) hypertensive rats. There was 
no difference in the slope of the two lines.
3.3 EXPERIMENT Kb).
Effects of acute converting enzyme inhibition on blood 
pressure at the intermediate and chronic stages of 
two-kidney, one clip hypertension in the rat.
To test the accuracy of the angiotensin II / blood 
pressure regression line obtained for the chronic 
hypertensive rats a number of rats ranging from 8 to 20 
weeks after clipping were further studied with acute 
administration of converting enzyme inhibitor. Twelve 
rats from the 21 in the 4 week group were similarly 
studied even although these rats showed no detectable 
angiotensin II / blood pressure relationship.
3.3:1 Experimental design.
Thirty eight rats were studied further. Of these 
12 had been clipped 4 weeks previously and the other 26 
had been clipped between 8 and 20 weeks previously (Table 
3.2). After the blood pressure measurement and blood 
sampling had been carried out these were allowed to settle 
for 20 minutes to enable their blood pressure to stabilise 
if necessary. After this time an injection of angiotensin 
converting enzyme inhibitor nonapeptide, teprotide (lmg/kg 
in 0.1ml of sodium chloride (154 mmol/1: saline) was 
given via the carotid catheter and blood pressure was 
recorded for a further 5-8 minutes. Following this blood 
samples were taken for the measurement of angiotensin II,
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Number of weeks clipped Number of rats
4 12
8 6
9 3
10 3
15 7
20 7
Table 3.2 Rats studied further.
plasma renin concentration and angiotensin converting 
enzyme (0.85ml total). The rats were then killed as 
described above (3.2:1).
3.3:2 Results.
(i) Blood pressure. (Figure 3.6(i))
Chronic hypertensive rats: There was no difference in the
mean basal blood pressure of the 26 chronic hypertensive 
rats (179.3 +/-17.1 mmHg) as compared with any of the 
individual groups from 8 to 20 weeks after clipping.
After the administration of the converting enzyme 
inhibitor there was a rapid and significant fall in blood 
pressure which levelled out between 3 and 5 minutes to a 
minimum of 150.0 +/- 20.6 mmHg at 5 minutes. Of these 26 
rats, 12 were from the 8, 9 and 10 week groups and 14 were 
from the 15 and 20 week groups. The hypotensive response 
for the 15 and 20 week late chronic hypertensive rats was 
smaller (177.3 +/- 16.1 falling to 163.1 +/- 17.3 mmHg) 
than for the earlier 8, 9 and 10 week groups (181.1.+/- 
18.8 falling to 154.2 +/- 17.3 mmHg) but this difference 
was not significant. With the exception of one rat, none 
of the 26 rats studied had a blood pressure, after 
converting enzyme inhibition, within the normal range 
found for sham-operated rats.
Intermediate 4 week rats: The 12 intermediate 4 week rats
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3.6 Changes in blood pressure (i) angiotensin
II (ANGII) (ii) and plasma renin (PRC) (iii) 
in 26 chronic hypertensive rats (8-20 weeks, 
•) and 12 intermediate hypertensive rats (4 
weeks, X) given an acute injection of 
angiotensin converting enzyme inhibitor 
nonapeptide (lmg/kg/0.lml), and six chronic 
hypertensive control rats (O) given saline 
(0.1ml). Bars show +/- SEM. Significant 
changes (paired t-test) are compared with 
basal values: **** p<0.001; *** p<0.01.
had a basal blood pressure of 151.8 +/- 29.9 mmHg which 
was not significantly different from that of the 21 rats 
in the 4 week group as a whole. This basal blood pressure 
was significantly higher than that of the 1-2 day acute 
rats (116.7 +/- 3.9 mmHg, p<0.001) and significantly lower 
than that of the 26 chronic rats studied (179.3 +/- 17.1 
mmHg, p<0.001). Following administration of converting 
enzyme inhibitor the blood pressure in this group showed a 
small fall to a minimum of 144.7 +/- 29.8 mmHg after 5 
minutes. This fall in blood pressure was not significant.
(ii) Angiotensin II. (Figure 3.6(ii))
Chronic hypertensive rats: For all 26 rats there was a
significant fall in angiotensin II levels from a high 
basal level of 133.6 +/- 97.0 fmol/ml to a concentration 
at 5 minutes of 22.1 +/- 12.8 fmol/ml, which was well 
below normal values as found for the equivalent 
sham-operated rats (44.1 +/- 13.4 fmol/ml ).
Intermediate 4 week rats: The basal angiotensin II levels
for these 12 rats was 55.0 +/- 5.8 fmol/ml. This was 
similar to the 4 week group as a whole, but in contrast to 
the blood pressure it was significantly lower than that 
found for the 1-2 day acute rats (89.7 +/- 8.9 fmol/ml, 
p<0.001). After.converting enzyme inhibition angiotensin 
II was again supressed significantly, falling to 18.0 +/- 
9.1 fmol/ml at 5 minutes.
(iii) Plasma renin concentration. (Figure 3.6(iii))
Chronic hypertensive rats: The high basal levels of
plasma renin concentration rose markedly and significantly 
after converting enzyme inhibition from 128.2 +/- 116.7 to 
1936 +/- 1306 pmol Angl/ml/h (p<0.001).
Intermediate 4 week rats; The plasma renin concentration 
for these rats had risen significantly at 5 minutes after 
administration of converting enzyme inhibitor from 18.7 
+/- 13.2 to 550 +/- 377 pmol Angl/ml/h (pcO.OOl).
The fall in blood pressure for the 26 chronic 
hypertensive rats was significantly related to both the 
basal angiotensin II concentration (r= 0.80, p<0.001) 
(Figure 3.7) and to the basal plasma renin concentration 
(r= 0.61, p<0.001). In the 4 week intermediate group 
there was no detectable correlation between the fall in 
blood pressure and either basal angiotensin II or basal 
plasma renin concentrations.
(iv) Control rats.
Six chronic hypertensive rats (9, 10 and 12 weeks)
. were given an injection of saline instead of converting 
enzyme inhibitor. These rats showed no changes in blood 
pressure (Figure 3.6(i)), angiotensin II (Figure 3.6(ii))
88.
100 _
bJD
Xs
£
w
r = 0.80, P< 0.001
75 -
co
w
P4
8
tt
<J
5 0 -
2 5 -
• •
~i—  
100 200 300 400
Basal ANG EE (fmol m l” plasma)
Figure 3.7 Correlation between the fall in blood
pressure and basal angiotensin II (ANGII) 
in chronic hypertensive rats given 
converting enzyme inhibitor.
or plasma renin concentration (Figure 3.6(iii)).
(v) Serum converting enzyme.
Serum converting enzyme was measured in the 4 week 
intermediate rats before (2.5 +/- 0.52 umol hippuric acid 
/ml/h) and after (0.21 +/- 0.17 umol hippuric acid /ml/h) 
administration of converting enzyme inhibitor. This 
confirms a greater than 90% inhibition.
3.4 Commment.
Figure 3.8 shows the angiotensin II / blood 
pressure regression lines for both acute and chronic rats 
as determined for Figure 3.5. Superimposed on these are 
the mean hypotensive responses following converting enzyme 
inhibition for the 26 chronic rats and the 12 intermediate 
rats. It can be seen from this that the hypotensive 
response of the 26 chronic rats follows closely both the 
slope and the position of the regression line for all the 
chronic hypertensive rats thus confirming the regression 
line as a fairly accurate representation of the acute 
effects of angiotensin II in chronic renal hypertension in 
rats.
The very small fall in blood pressure after 
converting enzyme inhibition in the 4 week intermediate 
rats indicates that the suppressed levels of angiotensin 
II at this stage do not contribute significantly to the
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Figure 3.8 Mean angiotensin II and blood pressure
values, before and 5 minutes after giving 
converting enzyme inhibitor, for 26 chronic 
{8-20 weeks, •) and 12 intermediate (4 week, 
O) hypertensive rats, superimposed on the 
angiotensin II/blood pressure regression 
lines for acute (1-2 day (l) ) and all chronic 
(8-20 weeks (2) ) hypertensive rats. Bars show 
+/- SEM.
hypertension. From Figure 3.8 it can be seen that this 
fall in blood pr.essure in the 4 week rats follows the 
slope of the regression lines for both the chronic and 
acute rats, but is positioned at the lower unresponsive 
range. This indicates that the net vascular 
responsiveness during this intermediate phase is the same 
as for the acute and chronic stages and thus the 
discrepancy between the rising blood pressure and the low 
angiotensin II at this intermediate stage cannot be 
accounted for by an increase in sensitivity. The fact 
that the line showing the fall in blood pressure for the 4 
week rats is positioned upwards from the regression line 
for the acute rats and is nearer to that for the chronic 
rats again suggests the onset of some other mechanism 
other than the acute effect of angiotensin II which must 
be mainly responsible for the developing hypertension, 
even at this early stage. One possible explanation for 
this other mechanism is that angiotensin II may be acting 
through a slow chronic effect on blood pressure as well as 
its acute pressor effect. In order to test this the next 
experiment was devised to compare the effects on blood 
pressure of captopril administered acutely and chronically 
to rats with established hypertension (ie rats in the 
chronic stage).
CHAPTER 4
AN EXAMINATION OF THE SEPARATE EFFECTS OF ACUTE AND 
CHRONIC INHIBITION OF CONVERTING ENZYME ON BLOOD PRESSURE 
IN TWO-KIDNEY, ONE CLIP RATS WITH ESTABLISHED 
HYPERTENSION.
4.1 Introduction.
To summarise so far:
Three overlapping stages in the development of the 
hypertension in the two-kidney, one clip rat have been 
identified. The first of these is the acute stage, where 
blood pressure, angiotensin II and plasma renin 
concentration are all elevated, the second is the 
intermediate stage where blood pressure is continuing to 
rise but both angiotensin II and plasma renin 
concentration fall towards normal levels and thirdly, the 
chronic stage where the hypertension has become 
established and angiotensin II and plasma renin 
concentration again are rising. The previous experiment 
has suggested that in the acute stage it is the rise in 
angiotensin II which is responsible for the hypertension 
and has suggested that in the intermediate and chronic 
stages, because the acute administration of converting 
enzyme failed to return the pressure to normal levels 
during these stages, some other mechanism is responsible 
for the greater part of the hypertension. Angiotensin II
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has been shown to have a slow pressor effect when infused 
at a dose below the threshold of the direct pressor 
effect. This has been demonstrated in rabbits (Dickinson 
& Lawrence, 1963) , dogs (McCubbin et al.,1965; Cowley & 
McCaa,1976? DeClue et al.,1976; Bean et al.,1979) and rats 
(Koletsky, Rivera-Velez & Pritchard,1965; Brown et 
al.,1981,1983) and it may be a possible explanation of the 
second mechanism involved. One way of testing this is to 
infuse captopril chronically to rats whose hypertension 
was already established and to compare the fall in 
pressure with that occurring following the acute 
administration of captopril. If the fall in blood 
pressure with the chronic captopril is greater than with 
the acute captopril this would provide additional evidence 
to support the notion that the other mechanism was at 
least in part due to the secondary slow effect of 
angiotensin II on blood pressure although there is always 
the alternative explanation that converting enzyme 
inhibitors act by kinin potentiation.
4.1:1 Experimental Design.
Table 4.1 shows the protocol for this experiment. 
Groups of up to 20 rats had a silver clip placed across 
their left renal artery at any one time, the right kidney 
being left untouched. Between 5 and 13 weeks after 
clipping, rats known to be hypertensive (their systolic
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Monday Tuesday Wednesday Thursday Friday Saturday Sunday
Day 1 Day 2 Day 3 Day 4 Day 5
Implant
catheters
into aorta + IVC
Weigh rat
Rats into
experimental
cages
1000
Start continuous 
BP reading
0900-1000
1.Blood sample 
for All + PRC
/0.75ml]
2. Al injection 
(100ng/0.1ml)
10:00
Captopril
injection
(2.5mg/kg/0.1ml)
10:15 
Al (100ng)
1700 
Al (100ng)
1000
1. Al(IOOng)
2. Start chornic 
captopril/ 
dextrose 
infusion 
(1mg/kg/h)
1200 
Al (100ng)
1000  
Al (100ng)
1000 
Al (100ng)
Day 6 Day 7 Day 8 Day 9
10.00 
Al (100ng)
10:00 
Al (100ng)
0900-10:00
1. Blood sample 
for All + PRC 
(0.75ml)
2. Al (100ng)
1000
Stop infusion
1700
Al (100ng)
1000 
Al (100ng)
09:00-1000
1. Blood sample 
for AH + PRC 
(0.75ml)
2. Al (100ng)
1100
1. Kin rat
2. Weigh
Table 4.1 Protocol for Experiment 2
pressure having been measured by tail plethysmography) 
were chosen and catheters were implanted in their 
abdominal aorta and IVC. After 2 days they were placed in 
their experimental cages and extensions were fitted to the 
catheters. At lO.OOh on the third day (day 1) the 
arterial line was connected via the pressure transducer to 
the blood pressure recorder which in turn was connected to 
an Apple lie microcomputer (see 2.5:1). Blood pressure 
was then recorded continuously throughout the 9 days of 
the experiment both on the paper chart from the recorder 
and at 10 minute intervals by means of the computerised 
data collecting and analysis system. Apart from an 
initial comparison between blood pressures of 4 rats 
calculated by hand from the recorder chart and those 
obtained from the computer (see 4.1:2(ii)), all the long 
term pressure measurements quoted for this study were 
obtained using the computer. These pressures were 
calculated as the 4 hourly mean of measurements taken at 
10 minute intervals starting on day 1. Acute changes in 
pressure following both captopril and angiotensin I 
injections were calculated from the recorder chart. At 
lO.OOh on day 2, after the 24 hour basal period, blood 
(0.75ml) was removed for the measurement of angiotensin II 
and plasma renin concentration. Following this captopril 
was administered as a bolus injection (2.5mg/kg/0.lml) via 
the venous catheter. After a further 24 hour period a 
chronic infusion was begun. The test rats were infused 
with captopril (lmg/kg/h in heparin/dextrose, 150
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units/ml) and control rats with heparin/dextrose (150 
units/ml) at an infusion rate of lml/24hours. After 5 
days the infusion was stopped and blood (0.75ml) was 
removed for angiotensin II and plasma renin concentration 
measurements. Blood pressure was recorded for a further 2 
days at the end of which a final blood sample (0.75ml) was 
taken. As a test of the effectiveness of both acute and 
chronic captopril treatment to inhibit angiotensin 
converting enzyme activity and hence block the formation 
of angiotensin II, angiotensin I (100ng/0.lml) was 
injected via the arterial catheter at the end of the basal 
period, after acute administration of captopril (at 15 
minutes, 7 hours and 24 hours), during the chronic 
infusion of captopril (2, 24, 48, 72, 96 and 120 hours 
after the start of the infusion) and during the 2 
post-infusion days (7, 24 and 48 hours after the end of 
the infusion). All values quoted in the results are mean 
+/- standard deviation.
4.1:2 Results.
(i) Number of rats studied.
24 rats were studied all of which were given 
captopril acutely. Of these, 16 were subsequently infused 
with captopril (test) and 8 were infused with dextrose 
(control) . No more than 4 rats were studied at any one
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Figure 4.1 Correlations between blood pressures
calculated manually from the recorder chart 
and mean pressure as collected and 
calculated by computer for 4 rats. Each 
point is the 4-hourly mean of 10 minute 
measurements over a 9 day period.
time, at least one of which was always a control.
(ii) Comparison of manual and computer calculated blood 
pressures.
A comparison between the mean arterial pressures 
calculated by hand from the recorder chart and the mean 
arterial pressures calculated by the computer was carried 
out for 4 rats. Of these, 3 were infused chronically with 
captopril and one was infused with dextrose. Each rat was 
connected to a different recorder channel and the 
comparison was carried out for the full 9 days of the 
study. Figure 4.1 shows the results of this comparison. 
There is a highly significant correlation in each case, 
the only discrepancy being that two of the recorder charts 
gave slightly higher vaiues than the computer for 
pressures below lOOmmHg. This was confirmed as an 
innacuracy in the recorder during calibration with the 
external pressure standard. Thus the computer method was 
proved to be more accurate and so was used throughout the 
remainder of the study.
(iii) Changes in blood pressure.
Figure 4.2 shows the continuous blood pressure 
profile for both groups of rats for the 9 day experiment. 
Each day is a 24 hour period from lO.OOh to lO.OOh. Apart 
from the solid and open triangles, all the points
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represent the 4 hourly mean of pressures taken at 10 
minute intervals. The solid and open triangles represent 
the mean of 10 minute pressure measurements before the 
acute injection of captopril and the lowest individual 
pressure measurement after the captopril injection.
Basal daily blood pressure ranges for the test and 
control animals were similar on day 1 (ranges: 156.6 +/-
18.5 to 166.3 +/- 16.8 and 155.9 +7-25,1 to 163.9 +/- 31.0 
mmHg respectively).
(a) Acute captopril injection.
After the injection of captopril on day 2 a rapid 
fall in blood pressure was seen in both groups of animals 
(Figure 4.3). Pressure fell to a minimum 10 to 15 minutes 
after the injection and then began to rise again. The 
fall in blood pressure was similar for both groups (165.1 
+/- 19.4 to 137.6 +/- 23.3 mmHg for the test group and 
161.9 +/- 29.2 to 133.0 +/- 24.2 mmHg for the control 
group). Twenty four hours after the captopril injection 
blood pressure in both groups had returned towards 
pre-injection values (Figure 4.2).
(b) Chronic infusion of captopril.
Following the start of the chronic captopril 
infusion on day 3 pressure in this group fell reaching a 
minimum at 12 hours of 112.5 +/-19.4 mmHg. During the
Figure 4
170
160 -
150 -
o>
o_ 140 -CO
cro
<v
130 -
120 -
110
Will*!]!*
© 9 _ o
9 9 T o 9
JH*III
T--------1-------1-------1------ 1------1-------1-------1-------1---- 1-------\
0 2 4 6 8 10 20 30 40 50 60
Minutes
Captopril
injection
(2.5mg/kg)
3 The acute fall in mean arterial blood 
pressure following the injection of 
captopril in rats subsequently given a 
chronic infusion of captopril (O) and in 
rats given a chronic infusion of dextrose 
(•). The first point of each group 
represents the mean of 10 one minute 
measurements before captopril was given. 
All other points are individual 
measurements. Bars represent 1 SEM. 
Asterisk indicates the lowest individual 
blood pressure for each group.
first 36 hours after the start of the infusion, pressures 
in this captopril-infused group remained significantly 
lower than those seen following the acute injection of 
captopril. After this pressure tended to rise reaching a 
plateau during the third day of the infusion and while it 
was always lower than that seen after the acute captopril 
injection it was only significantly so during the troughs 
of diurnal variation. In the dextrose-infused control 
group pressure rose gradually throughout the experiment. 
During the chronic infusions pressure in the 
captopril-infused group was always significantly lower
(p<0.001) than that for the dextrose controls. By day 5
of the infusion for the captopril treated rats daily 
pressures ranged from 122.1 +/- 23.4 to 136.0 +/- 30.2 
mmHg while the range for the dextrose control rats was
163.6 +/- 23.8 to 180.4 +/- 22.5 mmHg. After stopping the
captopril infusion pressure started to rise within 4 hours
and continued to do so for 2 days after which it was 
similar to that for the dextrose-infused control group 
(daily ranges: 151.1 +/- 19.4 to 158.5 +/- 19.6 mmHg for 
the captopril-infused group and 162.5 +/- 26.6 to 173.7 
+/- 31.0 mmHg for the dextrose-infused group) (Figure 
4.2).
(iv) Angiotensin I challenge.
The results are shown in Figure 4.4. Fifteen 
minutes after the acute captopril injection the pressor
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response to the angiotensin I was less than 5% of the 
pre-treatment values for both groups of rats. After 7 
hours the response had returned to 69% and 53% 
respectively, and by 24 hours, just before the start of 
the chronic infusions, the response for both groups had 
returned to pretreatment values. Two hours after the 
start of the chronic infusions the pressure response of 
the captopril group had fallen to 21% of that for the 
dextrose group which remained unchanged. Throughout the 
rest of the infusion the pressor response for the dextrose 
group remained the same while that for the captopril 
treated group was always less than 5% of that found for 
the dextrose group. Seven hours after the infusion was
stopped the response for the captopril group had returned
to 78% of that for the dextrose control group and at 24 
and 48 hours there was no difference between the responses 
of the 2 groups of rats.
(v) Changes in angiotensin II.
The basal angiotensin II value at the end of day 1
for the test animals was 72.6 +/- 52.0 fmol/ml. At the
end of the 5th day of the captopril infusion this had 
fallen to 17.2 +/- 8.0 fmol/ml and two days after stopping 
the infusion had risen to 57.4 +/- 6.5 fmol/ml. The 
angiotensin II levels for the dextrose group remained 
relatively unchanged throughout the experiment, 94.1 +/-
50.1 fmol/ml at the end of day 1, 65.0 +/- 22.9 fmol/ml at
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the end of the dextrose infusion and 57.4 +/- 15.5 fmol/ml 
2 days after stopping the infusion.
(vi) Changes in plasma renin concentration.
For the test animals the basal plasma renin was
44.6 +/-44.1 pmol Angl/ml/h. This had risen to 332.4 
+/-62.9 pmol Angl/ml/h by the end of the 5th day of 
captopril infusion and 2 days after stopping the infusion 
it had fallen back to 30.0 +/- 44.9 pmol Angl/ml/h.
Plasma renin values for the dextrose-infused group 
remained unchanged throughout (40.3 +/- 50.1, 32.2 +/-
18.5 and 31.2 +/- 21.0 pmol Angl/ml/h respectively).
(vii) Relationship between blood pressure fall and basal 
angiotensin II and plasma renin concentration.
(a) Acute captopril injection. The fall in blood 
pressure was significantly related to the basal 
angiotensin II and plasma renin concentrations for both 
groups combined (r = 0.87 and 0.82 respectively, p <
0.001, n=24).
(b) Chronic captopril infusion. Table 4.2 shows the 
relationship between the fall in blood pressure with 
increasing duration of captopril, and basal angiotensin II 
and plasma renin concentration. The correlation remained
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Hours of 
captopril
PRC 
r P
Ang.II 
r P
24 0.65 <0.01 0.60 <0.02
48 0.61 <0.02 0.40 NS
72 0.52 <0.05 0.40 NS
96 0.63 <0.01 0.48 NS
120 0.70 <0.01 0.57 <0.05
NS = not significant
Table 4.2 Correlation between the fall in blood 
pressure with increasing duration of 
captopril infusion and basal plasma renin 
concentration (PRC) and angiotensin II 
(Ang.II).
significant throughout the infusion for plasma renin 
however for angiotensin II it was either just significant 
or not significant.
4.2 Comment.
From Figure 4.2 it can be seen that the chronically 
infused captopril did cause a greater fall in blood 
pressure in those rats with already established 
hypertension than did the acute administration of 
captopril. Although the mechanism involved remains 
uncertain these results do seem to support the suggestion 
that a second effect of angiotensin II may be involved. 
However as can be seen, this fall in blood pressure with 
the chronic captopril was not entirely sustained 
throughout the 5 days of the captopril infusion which 
suggests that there might be a gradual onset of some other 
compensatory mechanism which possibly has been triggered 
as a consequence of the chronic suppression of angiotensin 
II.
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CHAPTER 5
GENERAL DISCUSSION.
5.1 Summary of main findings.
From the studies carried out here three main 
phases can be distinguished in the development and 
maintenance of hypertension in the two-kidney, one clip 
rat. These phases are not rigidly defined and 
considerable overlap between phases seems likely. The 
first or acute phase is present for 1-2 days after 
clipping when both blood pressure and angiotensin II are 
found to be raised. Following this is the second or 
intermediate phase when blood pressure is continuing to 
rise but angiotensin II and plasma renin are found to be 
suppressed. The third chronic stage occurs when 
hypertension has become established and plasma renin and 
angiotensin II are again elevated. In this study the 
chronic stage was established at 5-7 weeks after clipping. 
During both the acute and chronic stages there was a 
significant relationship between blood pressure and 
angiotensin II. In contrast there was no relationship 
during the intermediate stage. Acute administration of 
converting enzyme inhibitor to rats in the chronic stage 
produced a significant fall in blood pressure. However 
this fall failed to return blood pressure to within the
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normal range found for sham operated rats. There was no 
significant fall in blood pressure after acute converting 
enzyme inhibitor administration to rats in the 
intermediate stage. This suggests that an increase of the 
acute vasoconstrictor effect of angiotensin II was not 
important in the development and maintenance of the 
hypertension during these stages and that some other 
mechanism must be involved. In the second study, chronic 
administration of converting enzyme inhibitor to rats in 
the chronic phase with established hypertension resulted 
in a greater fall in blood pressure than that produced by 
the acute injection alone suggesting that this other 
mechanism mayb@q,second effect of angiotensin II.
5.2 Sequence of events in the development of the 
hypertension.
Figure 5.1 shows the proposed sequence of events 
for the progressive changes in blood pressure and 
angiotensin II during the onset, development and 
establishment of the hypertension. The mean values for 
angiotensin II and blood pressure at different stages from 
acute to chronic hypertension are related to the 
angiotensin II/blood pressure regression lines found for 
the acute and■chronic rats.
Immediatly (1-2 days) after application of the 
clip blood pressure and angiotensin II rise, moving up the
lower, acute, regression line relating angiotensin II and 
blood pressure, angiotensin II being mainly responsible 
for the rise in blood pressure at this time. Two weeks 
after clipping angiotensin II is suppressed while blood 
pressure remains elevated, angiotensin II now being again 
at the lower end of the dose response curve and therefore 
having little or no acute effect on blood pressure at this 
stage. At 4 weeks angiotensin II has moved up the dose 
response curve slightly but is still suppressed compared 
to the 1-2 day acute stage and so will have only a small 
effect on blood pressure. In contrast blood pressure has 
risen considerably at 4 weeks to an extent which cannot be 
accounted for by the angiotensin II concentration. At 7 
weeks blood pressure continues to rise and angiotensin II 
has also increased. As angiotensin II has moved up the 
dose response curve its acute effect will also have 
increased but this effect will still be small in relation 
to the increase in blood pressure. Thus the acute effect 
of angiotensin II during the period of 5-7 weeks after 
clipping varies according to its position on the dose 
response curve. This acute effect however is overshadowed 
by, and superimposed on top of, a continuously developing 
and much more important mechanism whose onset appears to 
be as early as 2 weeks and which reaches its maximum 
effect at 5-7 weeks after clipping having shifted the 
regression line found for the acute rats upwards in a 
parallel fashion to that position found for the chronic 
rats.
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Figure 5.1 Progressive changes in angiotensin II and
blood pressure during the onset, development 
and establishment of hypertension in the 
two-kidney, one clip hypertensive rat in 
relation to the upward parallel shift in the 
angiotensin II/blood pressure regression 
line from that found for the acute (1-2 day 
@  ) to that found for the chronic (8-20 
weeks (2)) hypertensive rats. Values are the 
mean +/- SEM for all sham-operated rats (•), 
1-2 day clipped rats (O), 2 week clipped 
rats (A), 4 week clipped rats (X) and 7 week 
clipped rats (A). (See 3.2 for details)
5.3 Mechanisms at work during the different stages in
the hypertension.
5.3:1 Acute stage.
In this study the acute stage was represented by 
the 1-2 day rats. At this time blood pressure, 
angiotensin II and plasma renin were all raised compared 
to the sham operated rats. This observation agrees with 
the findings of most other workers (Brown et al.,1966; 
Blair-West et al.,1968; Bianchi et al.,1972; Liard et 
al.,1974; Carretero and Gulati,1978). Previous studies 
with angiotensin II inhibitors or antagonists (Pals et 
al.,1971; Thurston & Swales,1974a; Coleman & Guyton,1975; 
Miller et al.,1975; Freeman et al.,1977b? Masaki et 
al.,1977; Carretero and Gulati,1978) and studies involving 
angiotensin II or renin dose response measurements 
(Bianchi et al.,1972; Caravaggi et al.,1976) suggest that 
the raised angiotensin II and plasma renin levels found 
immediatly after clipping are wholly responsible for the 
hypertension at this time.
The increased renin and angiotensin II levels are 
consequent on reduced renal perfusion pressure resulting 
from application of the clip to the renal artery (Selig et 
al.,1983). Angiotensin II then has a direct 
vasoconstrictor effect to raise blood pressure. The
104.
finding here of a significant angiotensin II/blood 
pressure relationship for the rats 1-2 days after clipping 
(acute rats) agrees with this, however complete 
confirmation of this would require angiotensin II infusion 
studies to verify that the regression lines were 
superimposible as has been shown in the dog (Caravaggi et 
al.,1976). Comparison with a previous study of acute 
angiotensin II infusions in the rat carried out in this 
department by Brown et al. (1981) suggests that the 
regression line obtained for the acute animals is a fairly 
accurate representation of the true effects of endogenous 
angiotensin II.
5.3:2 Intermediate stage.
The intermediate stage in this study occurs 
between 2 and 5 weeks after clipping. During this time 
blood pressure continues to rise but angiotensin II and 
plasma renin are suppressed and do not start rising again 
until after 4 weeks. No significant relationship between 
angiotensin II and blood pressure was found at this time, 
and acute administration of converting enzyme inhibitor 
had little effect on blood pressure. It is likely 
therefore that plasma angiotensin II by its acute 
vasoconstrictor effect plays little or no part in the 
hypertension at this stage. These observations pose 3 
questions. Firstly why are angiotensin II and plasma 
renin lower between 2 and 4 weeks, secondly why does blood
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pressure continue to rise in the face of the suppressed 
renin-angiotensin system and thirdly what causes the 
secondary and progressive rise in angiotensin and renin 
after 4 weeks.
In addition to the biological mechanisms involved 
there is the possibility of an artifactual result 
answering the first question arising from the 
cross-sectional design of the study. It is possible that 
the suppressed levels of renin and angiotensin II found 
between 2 to 4 weeks arises because rats chosen for study 
at this time are in fact normotensive and would not 
subsequently develop hypertension. However as the same 
procedures were used throughout the study and the 
incidence of hypertension which developed was consistent 
at about 80% and rats were chosen at random for study in 
each group then it is likely that rats chosen for the 2 to 
4 week groups contained the same proportion of animals 
which would subsequently become hypertensive. Also in the 
separate experiment where systolic blood pressure was 
measured sequentially in a group of rats it was shown that 
rats which develop hypertension in the chronic stages up 
to 20 weeks have only slightly elevated blood pressures 
between 2 and 3 weeks. This is similar to the findings in 
main cross-sectional study.
A physiological mechanism to explain the 
suppression of angiotensin II and plasma renin between 2 
and 4 weeks is sodium retention. Raised angiotensin II in 
the acute stage would have a sodium retaining effect via
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aldosterone stimulation. Increased sodium retention would 
in turn have a negative feedback effect to suppress renin 
and All. Such a proposal has been put forward by both 
Ledingham (1975) and Guyton et al. (1975). However 
evidence for sodium retention is unclear in this renal 
model. Some studies find a positive sodium balance at 
this time (Leenen & DeJong,1975; Mohring et al.,1975) 
while others find no change or a negative balance 
(Blair-West et al.,1968; Tobian et al.,1969; Bianchi et 
al.,1972; Swales et al.,1972). In a study carried out in 
this department by McAreavey et al. (1982) using 
two-kidney, one clip rats, there was no significant 
difference in exchangeable sodium between clipped and sham 
operated rats up to 6 weeks after clipping. Evidence for 
a sodium retaining effect is therefore inconclusive.
An alternative explanation may be a return to 
normal of renal blood flow and renal artery pressure in 
the clipped kidney. In a study performed on dogs with 
one-kidney, one clip hypertension, (Selig et al.,1983) 
both renal blood flow and renal artery pressure were found 
to fall immediatly after application of the clip, however 
there is evidence that the subsequent increase in systemic 
blood pressure results in the return of both renal blood 
flow and renal artery pressure towards values found before 
clipping. This would in turn also produce a fall in renin 
and angiotensin II.
One possibility for the continuing rise of blood 
pressure in spite of the suppressed renin angiotensin
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system may be an increase in vascular reactivity to 
angiotensin II. However the fact that the slopes of the 
angiotensin II/blood pressure regression lines were the 
same for both the 1-2 day acute rats and the 8 - 2 0  week 
chronic rats, and the observation that the fall in blood 
pressure in both the chronic and the 4 week intermediate 
rats after acute converting enzyme inhibitor 
administration followed the slope of these regression 
lines indicates that the net vascular responsiveness to 
angiotensin II remains the same throughout the development 
and maintenance of the hypertension in this experimental 
model. This finding agrees with that of Marks et al. 
(1982) who found that the duration of the hypertension did 
not alter the vascular responsiveness of exogenously 
administered angiotensin II and studies in the dog also 
support this (Brown et al.,1979). Therefore the fact that 
in the intermediate stage blood pressure is raised while 
angiotensin II and plasma renin are suppressed cannot be 
accounted for by an increase in sensitivity to angiotensin 
II and suggests that some other mechanism must be 
responsible for the continuing rise in blood pressure in 
the face of a suppressed renin angiotensin system. 
Possibilities for this mechanism will be discussed in a 
later section.
The most likely explanation for the rise in 
angiotensin II. and renin starting at 4 weeks is a 
progressive loss of sodium as the rats enter the malignant 
phase of hypertension (Gavras et al.,1975; Mohring et
al.,1975). This is supported by the fact that in 
experiment 1 the clipped rats were found to be lighter in 
weight at 5 to 6 weeks than their equivalent sham operated 
rats, this difference becoming significant at 8 weeks.
5.3:3 Chronic stage.
The chronic stage occurs when the hypertension has 
become established and both angiotensin II and plasma 
renin concentration are elevated. In this study this 
phase is taken as 8 to 20 weeks after clipping. Much of 
the work previously published suggests that in chronic 
hypertension plasma renin levels are found to be normal 
(Koletsky et al.,1967; Oates, Stokes & Storey,1975; 
Carretero & Gulati,1978; Russell et al.,1982). There are 
a number of possible reasons for this difference. First, 
different blood sampling techniques may have been used. 
Anaesthetic is known to be a stimulus to renin secretion 
(Leenen & De Jong,1975) and values for renin measurements 
for samples from normal rats taken under anaesthesia are 
10 to 20 times the values found for this study (Koletsky 
et al.,1967; Oates et al.,1975; Russell et al.,1982). It 
is therefore possible that any important differences in 
plasma renin concentrations between clipped and sham 
operated or normal animals could be obscured by these 
gross levels of renin.
A second explanation may be that although the rats 
have been studied at the same chronological time, the
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hypertension may in fact be at a different stage in its 
development. Factors which could contribute to this 
include differences in the strain and sex of rat used, 
applying the clip to rats of different weights/ages, using 
a clip or ligature of different dimensions and applying it 
to different regions of the renal artery.
Another possible explanation for the low renin 
values found may be the severity of the hypertension that 
develops in individual rats during the chronic stage. As 
previously mentioned (3.2:2 (i)), rats which were found to 
be only mildly hypertensive in the late chronic stage 
(15-20 weeks) were excluded from this study in order to 
allow a comparison with the 8 to 10 week early chronic 
rats in which the severity of the hypertension was similar 
for both. In this study a highly significant relationship 
was found between angiotensin II and blood pressure in the 
8 to 20 week (chronic) rats (the lower the blood pressure 
the lower the angiotensin II and plasma renin 
concentration) and in fact a number of rats in the chronic 
stage which did not develop severe hypertension (ie blood 
pressure above 170mmHg) had relatively normal angiotensin 
II and plasma renin levels. These findings agree with 
those of Mohring et al. (1975) and Carretero & Gulati
(1978) and also explain the fact that rats can be divided 
into responders and non-responders after angiotensin II 
blockade, the angiotensin II/blood pressure regression 
line suggesting a continuous range of responses. Mohring 
et al. (1975) have suggested as a reason for this, that
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the rats with the lower blood pressure have come into 
sodium balance (responders) and thus the stimulation of 
plasma renin and angiotensin II is halted. The rats with 
the higher blood pressures (non responders) have not come 
into balance and are continuing to lose sodium and thus 
stimulate an increase in angiotensin II which causes a 
further rise in blood pressure which in turn results in 
further sodium loss. These rats will enter the malignant 
phase of hypertension via the vicious circle first 
described by Byrom & Dodson (1949) and will rapidly die. 
The early death of rats with severe or malignant 
hypertension and elevated plasma renin and angiotensin II 
will leave animals with less severe benign hypertension 
and low plasma renin and angiotensin II levels. This is 
the most likely explanation for the differences in renin 
and angiotensin II levels found in various studies of rats 
in the chronic stage. In the studies reported here it was 
found that rats with their left renal artery clipped did 
not grow as rapidly as the equivalent sham operated rats, 
this difference was seen as early as 6 weeks after 
clipping and became significant at 8 weeks (see Figure 3.3 
(i)). This suggests that perhaps some of these rats were 
entering the malignant phase of hypertension.
The mechanism sustaining the hypertension during 
this stage is not clear. As has been discussed earlier 
(5.2) the influence of the acute effect of angiotensin II 
on the hypertension at any stage is determined by its 
plasma concentration and its position on the angiotensin
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II/blood pressure dose response curve. The fact that this 
curve has shifted upwards in a parallel fashion in the 
chronic stage, and that although acute administration of 
converting enzyme inhibitor produced a significant fall in 
blood pressure, this fall failed to reduce the blood 
pressure to within the range found for the sham operated 
rats, ie only produced a partial correction of the 
hypertension, confirms previous observations (Thurston & 
Swales,1974a; Gavras et al.,1975; Carretero & Gulati,1978; 
Otsuka et al.,1979) that although the acute effect of 
circulating angiotensin II has some involvment at this 
stage, it is only partly responsible for the hypertension 
and therefore some other mechanism must be involved.
After chronic administration of converting enzyme 
inhibitor to rats in this chronic stage a greater fall in 
blood pressure than that seen with acute converting enzyme 
inhibitor administration occurred. This observation 
supports the notion that the other mechanism may also 
operate through angiotensin II. These results are similar 
to those found by Bengis and Coleman (1979) and the 
initial fall in blood pressure following the start of the 
captopril infusion was very similar to that shown by 
Riegger et al. (1977) who infused saralasin and the 
converting enzyme inhibitor teprotide to renal 
hypertension rats. However these observations are in 
contrast to those of Bing et al. (1981) and Russell et al. 
(1982) who failed to show any significant effect on blood 
pressure following a chronic infusion of either saralasin
or captopril. Brown et al. (1983) suggested that the 
discrepancy between the results of Riegger et al. and 
those of Bing et al. might be explained by the fact that 
the study of Riegger et al. (1977) was performed during 
the day, when blood pressure was in the trough of its 
diurnal variation, while that of Bing et al. (1981) was 
performed at night when blood pressure is at its peak and 
could obscure what otherwise might be a fall in blood 
pressure. This could also apply to the results of Russell 
et al. (1982) who also infused overnight. Some evidence 
to support this comes from the present study which shows 
that after the initial large fall, the blood pressure 
during the chronic captopril infusion was significantly 
lower than that after the acute injection only during the 
day, ie during the trough of diurnal variation.
The fall in blood pressure caused by chronic 
captopril administration was not wholly maintained 
throughout the 5 days of the infusion which suggests the 
gradual onset of some other compensatory mechanism, 
possibly as a consequence of the sustained suppression of 
angiotensin II. This situation is less likely to exist 
during oral administration of captopril as used by 
DeForrest et al. (1982) when there is probably daily 
escape from maximal angiotensin II suppression.
5.4 Possible second mechanisms.
I have shown that the acute effect of angiotensin 
II is not wholly responsible for the development and 
maintenance of the hypertension in these two-kidney, one 
clip rats and that some other mechanism, which appears to 
be responsible for the greater part of the hypertension, 
must be involved. The onset of this mechanism seems to 
occur as early as two weeks after clipping, when blood 
pressure continues to rise while angiotensin II and plasma 
renin are suppressed, and reaches its maximum effect at 
5-7 weeks. Chronic suppression of angiotensin II in rats 
with established hypertension by captopril infusion 
produced a greater fall in blood pressure than that seen 
after acute converting enzyme inhibitor administration, 
suggesting that this other mechanism operates through some 
secondary action of angiotensin II on blood pressure. 
Although there are a number of possibilities for this 
other mechanism, two of the most likely which involve the 
renin-angiotensin system are vascular renin and the slow 
pressor effect of angiotensin II.
5.4:1 Vascular Renin.
Renin and/or renin like enzymes have been found to 
be present in many tissues (Ganten et al.1976;1983; Naruse 
et al.,1983; Dzau et al. ,1-984; Deschepper et al.,1986; 
Sealey et al.,1987) including the blood vessel wall
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(Thurston & Swales,1974b? Naruse & Inagami,1982? Swales et 
al,1983a; Swales & Heagerty,1987). Arterial wall renin 
like activity appears to have two sources. It may be 
kidney derived renin taken up from plasma (Loudon et 
al.,1982,1983? Swales et al. ,1983a,1983b); changes in 
arterial renin levels parallel those of plasma renin and 
infusion of pressor quantities of renin in normal rats 
results in an increase of arterial renin, and it may be 
synthesised locally; synthesis of renin has been found in 
canine smooth muscle aortic cells and bovine endothelial 
aortic cells in culture (Re et al.,1982; Lilly, Pratt & 
Alexander,1985) and renin mRNA expression has recently 
been identified in a range of extra renal sites (Samani et 
al.,1987,1988). The relative importance of these two 
processes remains unknown.
Both angiotensin converting enzyme Miyazaki et 
al.,1984 and renin substrate have been found in the 
vasculature, angiotensin converting enzyme has been 
localised to the endothelial cell surface (Ryan et 
al.1976b; Johnson and Erdos,1977; Hial et al.,1979; Takada 
et al.,1982) and recently angiotensinogen mRNA sequences 
have been detected in many non liver sites (Dzau et 
al.,1986; Ohkubo et al.,1986) suggesting local synthesis. 
Thus it appears that all the necessary components of the 
renin-angiotensin system are present and angiotensin II 
could therefore be generated locally.
It is thought that local generation of angiotensin 
II within the arteriolar wall by vascular renin may be of
physiological and pathological importance perhaps by 
exerting local control over vascular vasoconstrictive 
activity (Dzau,1986; Swales & Heagerty,1987) the vascular 
angiotensin II levels not being reflected by circulating 
plasma angiotensin II levels. However demonstration of 
this in vivo is difficult, the problem being 
distinguishing between plasma and vascular renin effects. 
In studies where plasma renin levels were acutely reduced 
by bilateral nephrectomy in early two kidney, one-clip 
rats (Thurston & Swales,1977; Thurston et al.,1979) 
arterial renin was found to have a much longer half-life 
than plasma renin. This slow decline in vascular renin 
like activity was paralelled by a slow decline in the 
depressor response to blockade of the renin-angiotensin 
system suggesting vascular renin is of major importance in 
maintaining blood pressure. These observations fit with 
my own finding of a slow decline in blood pressure during 
chronic infusion of captopril in Experi-ment 2 and 
therefore offer a possible additional mechanism to the 
acute effect of the renin-angiotensin system. An 
explanation for the greater fall in blood pressure seen 
after chronically administered captopril than after acute 
administration could be that the local generation of 
angiotensin II occurs at a site which may not be so easily 
accessible to the captopril within the duration of the 
acute administration as has been suggested by Swales et 
al. (1983b).
5.4:2 The slow pressor effect of angiotensin II.
Angiotensin II infused over a prolonged period of 
time at a dose below the threshold of the direct pressor 
effect has been found to result in a slow rise of blood 
pressure. This has been demonstrated in the rat (Koletsky 
et al.,1965; Brown et al.,1981), rabbit (Dickinson & 
Lawrence,1963), dog (McCubbin et al.,1965; Cowley & 
McCaa,1976; DeClue et al.,1976; Bean et al.,1979) and man 
(Ames et al.,1965). The idea that the slow pressor effect 
might be important in the pathogenisis of hypertension was 
first suggested by Dickinson and Lawrence (1963). In the 
experiments described here there are a number of features 
which would lend support to the notion of a slow effect of 
angiotensin II on blood pressure:
(1) In the intermediate stage of the hypertension, after 
2 weeks, although angiotensin II and plasma renin are 
suppressed compared to their levels at 1-2 days, they are 
still raised compared to the levels found for the 
equivalent sham operated rats. In effect both angiotensin 
II and plasma renin were always slightly elevated during 
the intermediate 2-4 week period. Reasons for the fall in 
angiotensin II and plasma renin at this stage have already 
been discussed (5.3:2). Therefore while angiotensin II 
and plasma renin may not have been high enough to 
influence blood pressure acutely, the prospect of an 
underlying and increasing chronic effect cannot be ruled 
out, especially as the slow gradual rise in blood pressure
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at 2-5 weeks would fit with the slow pressor effect of 
angiotensin II. Additional evidence that this slow effect 
may be involved comes from the observation that chronic 
suppression of angiotensin II by converting enzyme 
inhibitor during the early stages of the disease (2-5 
weeks after clipping) prevented the development of the 
hypertension during this period (Wallace & Morton,1984). 
Similar findings have been reported by Freeman et al.
(1979) and DeForrest et al. (1982).
(2) Chronic administration of captopril to rats with 
established hypertension caused a greater fall in blood 
pressure than that found with acutely injected converting 
enzyme inhibitor suggesting a reversal of a slow effect of 
angiotensin II.
(3) After the chronic captopril infusion was stopped 
there was a progressive but slow return of the 
hypertension, which after 2 days had still not reached the 
same level as that seen in the control animals, further 
supporting the notion of a slow component operating 
through the renin angiotensin system.
5.4:3 Possible mechanisms of the slow pressor effect of 
angiotensin II.
A number of suggestions have been made as to the 
mechanism of the slow pressor effect of angiotensin II 
(Brown et al.,1977), some are discussed below.
(1) Action of angiotensin II on the nervous system.
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Evidence suggests that the nervous system may be 
involved in the slow pressor effect: (a) resetting of 
baroreceptors is partly responsible for the early rise in 
pressure produced by low dose angiotensin II infusion in 
the dog (Cowley & DeClue,1976) (b) central administration 
of angiotensin II modulates baroreceptor response 
(Fukiyama,1973; Goldstein et al.,1974; Marker, Miles & 
Scroop,1980) and raises arterial pressure (Lowe &
Scroop,1969), (c) drugs that interfere with nervous 
transmission prevent or attenuate the gradual rise of 
pressure (McCubbin et al.,1965; Yu & Dickinson,1971; 
Ferrario, Gildenberg & McCubbin,1972).
(2) An effect on salt and water excretion.
Angiotensin II alters urinary excretion of sodium 
and water (Brown & Peart,1962) and thus by acting directly 
or through aldosterone could cause sodium and hence water 
retention thereby raising blood pressure (Brown et 
al.,1976). While sodium restriction can prevent the slow 
rise in pressure in dogs, and dietary salt loading 
enhances it (Cowley & McCaa,1976), evidence that there is 
sodium retention in the two-kidney, one clip model is 
uncertain and controversial. Whether angiotensin II acts 
by stimulating aldosterone is also unclear. The balance 
of the evidence suggests that during chronic angiotensin 
II infusion the increase in aldosterone is not persistant 
or marked and that the sodium retaining effect of 
angiotensin II is more likely to be renal than adrenal
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(DeClue et al.,1976; Bean et al.,1979; Hall et 
al.,1979,1984).
(3) Structural changes during the slow effect.
A slow effect on pressure might result from 
progressive structural alteration to the vessel wall of 
small resistance vessels in the form of increasing wall 
thickness and thus wall:lumen ratio. This in turn would 
raise the resistance to flow at maximum dilatation and 
result in an increase in responsiveness to vasoconstrictor 
agents such as angiotensin II (Folkow,1971). This 
structural alteration (or vascular hypertrophy) may occur 
in response to raised pressure or may be due to a direct 
effect of angiotensin II itself. Lever (1986) has 
suggested that angiotensin II could increase both vascular 
smooth muscle cell numbers and size leading to a gradual 
onset of vascular hypertrophy with a resultant slow rise 
in arterial pressure involving the vascular amplifier 
first described by Folkow (Folkow, Grimby &
Thulesius,1958; Folkow,1978) in which minor but persistant 
overactivity of a pressor mechanism is amplified by 
hypertrophy, blood pressure rises slowly and severe 
hypertension results (Figure 5.2). It has been suggested 
that one of the ways that angiotensin II might exert this 
effect could be by acting as a mitogen or trophin for 
vascular smooth muscle. The pathway by which better known 
growth factors stimulate growth and protein synthesis in 
vascular muscle and other cells is illustrated in Figure
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Figure 5.2
reinforced
B P | Hypertrophy Trophic mechanism
Minor overactivity of a pressor mechanism 
(A) raises blood pressure (BP) slightly, 
initiating positive feedback (BCB) and a 
progressive rise in blood pressure. D and E 
are two additional signals. D: an abnormal 
or amplified hypertrophic response to 
pressure. E: increase of an agent causing 
hypertrophy directly (for example excess 
growth hormone).
5.3. Like these factors (Moolenaar et al.,1983;
L’Allemain et al.,1984; Owen,1984; Pouyssegur,1985) 
angiotensin increases inositol triphosphate within the 
cytosol and diacylglycerol within the cell membrane 
(Williamson et al.,1985; Bingham Smith,1986). As a result 
of the increase of diacyl glycerol and probably via 
protein kinase C, angiotensin II activates an amiloride 
sensitive Na+/H+ exchanger and sodium influx results 
(Brock, Lewis & Bingham Smith,1982; Bingham Smith &
Brock,1983; Berridge & Irvine,1984; Berk et al.,1987). 
These changes lead to a rise of intracellular pH which is 
generally accepted as a precursor condition for cell 
growth (Busa & Nuccitelli,1984; Mahnensmith &
Aronson,1985) and could lead to hyperplasia and 
hypertrophy. Such a process could explain the mitogenic 
effect of angiotensin II. There is some evidence to 
suggests that angiotensin II has a trophic or mitogenic 
action, for example it causes proliferation of vascular 
smooth muscle in culture (Campbell-Boswell &
Robertson,1981; Lyall et al,1988), stimulates ribonucleic 
acid (RNA) synthesis (Re & Parab,1984) and growth in 
fibroblasts (Schelling et al.,1979). It is possible that 
the local generation of angiotensin II by vascular renin 
(see 5.4:1) as well as circulating angiotensin II could 
play a part in this.
Although structural alteration would seem 
plausible as a mechanism for the slow effect of 
angiotensin II it is doubtful that the fall in blood
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Figure 5.3 Schematic and simplified representation of 
the main events in a signalling system 
activated by growth factors. Growth factor 
occupies a membrane receptor; 
phosphatidylinositol biphosphate (PIP) is 
hydrolysed by phosphodiesterase in the 
membrane releasing inositol triphosphate 
(IP3) into the cytosol and diacyl glycerol 
(DG) in the plane of the membrane. DG 
activates kinase C linked to an amiloride 
sensitive Na'VH’4' exchanger whose activity 
increases. Sodium enters the cell down an 
electrochemical gradient and protons are 
extruded resulting in an increased cell 
alkalinity.
pressure which was found in these studies, 12 hours after 
the start of captopril infusion to chronic hypertensive 
rats, could readily be attributed to reversal of 
structural changes which presumably would take longer to 
reverse (Lundgren,1974; Weiss,1974; Lundgren &
Weiss,1979).
(5) A combination of mechanisms.
It is not clear whether a single mechanism or a 
combination of mechanisms is responsible for the slowly 
developing pressor action of angiotensin II. The 
mechanisms discussed above are not mutually exsclusive: 
angiotensin II acting through the nervous system could 
affect salt and water balance and changes of sodium and 
water could modify the rise in pressure. Also changes in 
sodium status could affect wall/lumen ratio and hence 
vascular tone.
However although the evidence for the 1 other’ 
mechanism from the experiments carried out here is 
compatible with a role for the slow pressor effect in the 
development of chronic renal hypertension this does not 
establish it and other mechanisms, independant of the 
renin system, must not be excluded.
It must be pointed out that converting enzyme 
inhibitors such as captopril are not specific in their 
action. Converting enzyme inhibitors potentiate the 
response to exogenously administered bradykinin, a potent
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vasodilator (Engel et al.,1972) although there is evidence 
that captopril does not cause a rise in the plasma 
concentration of this vasodilator (Johnston et al.,1979).
5.5 Relevance of this study to the disease in man.
This study is clinically relevant because in man 
hypertension is often associated with unilateral renal 
disease and the commonest form of this disease is stenosis 
or occlusion of the renal artery. In the rat, Goldblatt 
two-kidney, one clip hypertension closely parallels the 
disease in man, both in the early stages where the rise in 
pressure immediatly following renal artery constriction is 
due to the direct pressor effect of the rise of 
circulating angiotensin II (Brown et al.,1976) and in the 
later stages where the upward shift of the angiotensin II/ 
blood pressure regression line in chronic hypertension 
obtained in the present study is remarkably similar to 
that seen in patients with chronic renal hypertension 
(Brown et al.,1979) and confirms the relevance of this 
experimental model as a tool for the investigation of 
human renal hypertension.
5.6 Conclusions.
This study has attempted to define more precisely 
the evolution of the renovascular hypertension in relation 
to the renin-angiotensin system in the two-kidney, one 
clip rat. Three main phases have been distinguished in 
the development and maintenance of the hypertension.
While in the first phase the raised blood pressure is the 
result of the initial rise of circulating renin and hence 
the direct pressor action of angiotensin II, in the later 
stages blood pressure is disproportionately high in 
relation to the plasma angiotensin II levels and some 
other mechanism must be involved. Vascular renin and/or 
the slow pressor effect of angiotensin II could at least 
in part be responsible for this,however other mechanisms, 
independant of the renin-angiotensin system, cannot be 
excluded.
APPENDIX 1
CONSTRUCTION OF CAROTID ARTERY CATHETER.
These catheters were constructed from a 10cm 
length of Tygon polythene, internal diameter 0.5mm, 
external diameter 1.52mm (Norton Plastics, Akron, Ohio) 
and a 2.5cm length of polythene tubing, internal diameter 
0.5mm, external diameter 0.8mm (800/100/140/100, Portex 
Ltd Hythe, Kent, England). One centimetre at one end of 
the Tygon tubing was enlarged by stretching it over a 
number 21 gauge hypodermic needle which had been filed 
smooth, then heating it against a hot light bulb, allowing 
it to cool and then removing the needle. The polythene 
tubing was then inserted into this widened 1cm and was cut 
straight across at the tip, a bevelled tip being more 
likely to either pierce the artery or to lie up against 
the artery wall thus making blood pressure recording 
impossible. The tip was then held against a hot light 
bulb in order to melt away any sharp edges. A 1cm plug 
was made from stainless steel wire (0.7mm diameter) which 
was rounded at both ends to prevent damage to the 
catheters. Figure 1 shows a carotid catheter.
2.5cm
Polythene tubing (0.5mm ID, 0.80D)
10cm Tygon (0.5mm ID, 1.520D)
1cm
1.5cm
Lying within the carotid artery
Figure 1 Carotid artery catheter.
APPENDIX 2
CONSTRUCTION OF AORTIC CATHETER.
This method was modified from the technique of 
Weeks & Jones (1960) (Browning, Ledingham & Pelling,1970). 
These catheters consisted of four pieces of polythene, A, 
B, C & D, welded together by heating. Figure 2 shows an 
aortic catheter.
Parts of the aortic catheter.
Part A: 17cm length of polythene tubing 800/100/200, 
internal diameter 0.58mm, external diameter 0.96mm (Portex 
Ltd, Hythe, Kent, England).
Part B: 0.5cm length of polythene tubing 800/100/280, 
internal diameter 0.86mm, external diameter 1.52mm (Portex 
Ltd).
Part C: 5cm length of polythene tubing 800/100/320, 
internal diameter 1.14mm, external diameter 1.5mm (Portex 
Ltd) .
Part D: 10 cm length of polythene tubing PE10, internal 
diameter 0.28mm, external diameter 0.61mm (Clay Adams, 
Becton, Dickinson and Company, Parsippany, N.J. 07054).
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Preparation of catheter parts before assembly.
Part B: The polythene was heated at one end until it was 
flared and then it was widened over a length of 18 gauge 
tinned copper wire which had been heated against a 
soldering iron. This stretched it sufficiently to fit 
over part A.
Part C: Approximately 1cm at one end of the polythene 
tubing was widened over a length of heated 16 gauge copper 
wire. This expanded it enough to be pushed over parts A 
and B.
Part D: The PE10 was threaded over stainless steel wire 
(0.2mm diameter), which had been previously greased with 
silicone fluid to make the threading easier. The 
polythene was heated approximately 4cm from the end in a 
hot air stream. When molten it was removed from the hot 
air and pulled out firmly to give a thin walled section 
3-5cm long. The drawn out tubing was trimmed to give a 
2.5cm length of normal walled tubing before the thin 
walled part.
Assembly of the catheter:
The neck piece. Part B, flared end first, was pushed over 
part A to about 5cm from the end. The widened part C 
tubing was then threaded over part A and onto part B.
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This join was heat sealed. This seal and the flange of 
part B formed an anchor point which was used to secure the 
catheter to the back of the neck with sutures. Further 
seals between part A and part C at approximately 1cm 
intervals were made. The final seal was cut through with 
a scalpel to ensure correct sealing.
Sealing part A to part D: 30cm of the 0.2mm diameter
stainless steel wire was inserted inside 20cm of 26 gauge 
needle tubing so that 5cm of wire protruded at each end. 
Part D was threaded over the wire and part A threaded over 
the needle tubing to overlap about 5mm of part D. This 
overlap was then heat sealed together over a soldering 
iron. Part A was heated 5-10mm from this seal until 
pliable and both ends were pushed together to form a ridge 
which was allowed to harden away from the heat. The seal 
and the ridge formed another anchor point for the 
catheter. Two more ridges 0.5cm apart were made as above 
on part D about 2cm from the join with part A, these 
formed the third anchor point for the catheter.
The S-bend: Part D was bent on a plastic former and held
in place with plasticine. This was dipped into boiling 
water and then set by cooling rapidly in iced water. The 
S-bend was such that the A-D junction was on the first 
bend, the anchor point on part D was just before the 
second bend and the thin walled part began at the top of 
the second bend.
The 90 degree bend on the neck piece: A bend was made at
the third heat seal on the neck piece. The neck piece was 
threaded over a length of 26 gauge needle tubing which had 
been previously been bent to an angle of 90 degrees so 
that it would protrude from the back of the neck at right 
angles when the catheter was in position. The needle 
tubing plus the neck piece was dipped into boiling water 
and set by cooling in iced water. On removing the needle 
tubing the 90 degree bend remained in the catheter.
Heat seals
90° bend here _
Part B — I
Anchor point
fr^
Pulled out section
Part D
Figure 2 Aortic catheter.
P a rte
Neck anchor point 
Part A
Anchor point
APPENDIX 3.
CONSTRUCTION OF IVC CATHETER.
The IVC catheter consisted of four pieces of 
polythene sealed together by heating. The materials used 
are identical to those in the aortic catheter construction 
(Appendix 2) with one exception; for part A, 19cm of 
polythene was used instead of 17cm as used for the aortic 
catheter. A constructed IVC catheter is shown in Figure 
3.
Preparation of catheter parts before assembly.
Parts B and C were prepared as for the aortic catheter.
Part D. 10cm of the PE10 polythene was threaded over a 
length of 0.2mm diameter stainless steel wire. The tubing 
was clamped at both ends with artery forceps. The 
polythene and wire were dipped into boiling water and then 
set by cooling rapidly in iced water. The wire was 
removed and the polythene was straight.
Assembly of the catheter.
The neck piece was assembled as for the aortic catheter.
130.
Sealing of part A to part D: The straightened length of
polythene (part D) was threaded onto the stainless steel 
wire protruding from the 35 gauge needle tubing. Part A 
was threaded over the needle tubing to overlap part D by 
about 5mm. This junction was heat sealed. Two 
centimeters from this seal on part A a ridge was made as 
before to form an anchor point.
The U-bend. A U-bend was made in the catheter by bending 
the part of the catheter distal to the anchor point on 
part A round the plastic former used for the aortic 
catheter. This was immersed first in boiling water and 
then in cold as before.
A 90 degree bend was made at the third seal on the neck 
piece as in the aortic catheter.
Neck piece i P a r t C -
■
it 
i  ■
Part A
Anchor point in_ 
R. Psoas muscle
Heat seals
90° bend here 
Neck anchor point 
Part B
Part D
Figure 3 Vena caval (IVC) catheter.
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